US Pat. No. 10,711,271

METHOD FOR MAKING A CDNA LIBRARY

BIOO SCIENTIFIC CORPORATI...

1. A method for making a cDNA library, comprising:(a) reverse transcribing an RNA sample that comprises mRNA to produce a first strand cDNA product;
(b) treating the first strand cDNA product with RNAaseH to produce a digested sample that comprises fragments of the mRNA; and
(c) reverse transcribing the mRNA fragments to produce a cDNA library.
US Pat. No. 10,709,735

IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has glioblastoma, comprising administering to said patient a population of activated CD8+cytotoxic T cells that kill the cancer cells that aberrantly present a peptide consisting of the amino acid sequence selected from SEQ ID NOs: 1, 2, 4, and 6-11 on the cell surface, wherein the peptide is in a complex with an WIC class I molecule, wherein the activated CD8+cytotoxic T cells are autologous to the patient, wherein the activated CD8+cytotoxic T cells are produced by contacting T cells in vitro with an antigen presenting cell comprising the peptide in a complex with an WIC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.
US Pat. No. 10,711,272

CTLA-4 APTAMER SIRNA SPECIES

City of Hope, Duarte, CA...

1. A nucleic acid compound comprising a monomeric CTLA-4 aptamer nucleic acid conjugated to a cell activity modulating nucleic acid, wherein the nucleic acid is an anti-cancer siRNA.
US Pat. No. 10,709,736

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 6,wherein said cancer is selected from AML (acute myeloid leukemia), BRCA (breast cancer), CCC (cholangiocellular carcinoma), CRC (colorectal cancer), GBM (glioblastoma), GC (gastric cancer), HCC (hepatocellular carcinoma), HNSCC (head and neck squamous cell carcinoma), MEL (melanoma), NHL (non-Hodgkin lymphoma), NSCLC (non-small cell lung cancer), OC (ovarian cancer), OSCAR (esophageal cancer), RCC (renal cell carcinoma), SCLC (small cell lung cancer), UBC (urinary bladder carcinoma), and UEC (uterine endometrial cancer).
US Pat. No. 10,711,273

AMINO ACID-MODIFIED NUCLEIC ACID AND UTILIZATION THEREOF

NATIONAL INSTITUTE OF ADV...

1. A method for synthesizing a protein, comprising the steps of:providing an mRNA having a modified codon inserted at a desired position downstream of a start codon; and
translating the mRNA into a protein in the presence of a tRNA acylated with a nucleobase amino acid (NBA) and recognizing the modified codon, wherein the NBA is an amino acid having a nucleobase as a side chain thereof, the nucleobase is selected from the group consisting of thymine (T), uracil (U), and derivatives thereof.
US Pat. No. 10,709,737

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 37,wherein said cancer is selected from colorectal cancer (CRC), gastric cancer (GC), hepatocellular carcinoma (HCC), and non-small cell lung cancer (NSCLC).
US Pat. No. 10,711,274

RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS

University of Massachuset...

1. A synthetic miRNA comprising 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 consecutive nucleotides encoded by a sequence set forth in SEQ ID NO: 17, and flanking regions of miR-155.
US Pat. No. 10,709,738

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 47,wherein said cancer is selected from colorectal cancer (CRC), gallbladder cancer (GBC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), ovarian cancer (OC), and renal cell carcinoma (RCC).
US Pat. No. 10,711,275

METHODS AND COMPOSITIONS FOR INTERFERENCE WITH DNA POLYMERASE AND DNA SYNTHESIS

Zhen Huang, Marietta, GA...

1. A method of inhibiting DNA synthesis in a cell, the method comprising bringing into contact RNA and the cell such that the RNA enters the cell and binds to DNA polymerase in the cell such that DNA synthesis in the cell is inhibited, wherein the RNA has a sequence complexity of 1X104 or more.
US Pat. No. 10,709,739

METHOD FOR CHEMOSELECTION

THE REGENTS OF THE UNIVER...

1. A method of radiation-free hematopoietic stem cell (HSC) transplantation, the method comprising:(a) engrafting into a pre-conditioned mammalian subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs; and
(b) immediately administering to the subject about 1 to 5 mg/kg of a purine base analog selected from 6-thioguanine (6TG), 6-mercaptopurine (6-MP), or azathiopurine (AZA) every two to four days for two to eight weeks;
wherein the method is performed in the absence of pre-conditioning via radiation.
US Pat. No. 10,711,021

METAL OXIDE-ORGANIC HYBRID MATERIALS FOR HETEROGENEOUS CATALYSIS AND METHODS OF MAKING AND USING THEREOF

YALE UNIVERSITY, New Hav...

1. A method of oxidizing an organic compound comprising one or more carbon-hydrogen bonds, the method comprising contacting the organic compound to be oxidized with an oxidant selected from the group consisting of a chemical oxidant, an electrochemical oxidant, and combinations thereof and a catalyst having the chemical formula;MYa(CO)bOc(OH)d(H2O)e
wherein
M is a d-block transition metal that forms stable carbonyl complexes selected from the group consisting of Cr, Mn, Co, Ni, Cu, Rh, Ir, and combinations thereof;
Y is a monodentate ligand, a bidentate ligand, or a combination thereof;
a is any value from 0.5 to 1;
b is any value from 0 to 3;
c is any value from 1 to 4; and
d is any value from 0 to 4; and
e is any value from 0 to 6,
to oxidize a carbon-hydrogen bond in the organic compound; and
wherein the catalyst is prepared according to a method comprising:
thermolysis of a solution comprising the d-block transition metal and the monodentate ligand, the bidentate ligand, or combinations thereof with stirring under reflux under an inert atmosphere;
allowing the resulting reaction mixture to cool followed by exposure to ambient atmosphere;
washing the reaction mixture; and
drying the washed reaction mixture to obtain the catalyst.
US Pat. No. 10,711,277

PLANT REGULATORY ELEMENTS AND METHODS OF USE THEREOF

PIONEER HI-BRED INTERNATI...

1. A recombinant nucleic acid molecule comprising a regulatory element operably linked to a heterologous polynucleotide, wherein the regulatory element comprises a polynucleotide selected from the group consisting of:(a) the polynucleotide of SEQ ID NO: 1, and
(b) a fragment of at least 283 nucleotides of SEQ ID NO: 1; and
and wherein the regulatory element has regulatory activity in a plant on the heterologous polynucleotide.
US Pat. No. 10,709,741

COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASE

NATIONAL UNIVERSITY CORPO...

1. A method of treating an inflammatory disease comprising, administering to a subject in need thereof an effective amount of a composition comprising a culture supernatant, wherein the culture supernatant is obtained by a method comprising(1) selecting adherent cells from dental pulp cells, and
(2) culturing the adherent cells to at least 70% confluence,
(3) culturing the cells obtained in step (2) in serum-free liquid, and
(4) obtaining the supernatant,wherein the composition does not contain dental pulp stem cells, andwherein the inflammatory disease is selected from the group consisting of fulminant hepatitis, hepatic cirrhosis, pulmonary fibrosis, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.
US Pat. No. 10,711,022

METHODS OF PRODUCING OLIGOSACCHARIDES FOR USE AS PREBIOTICS

WISCONSIN ALUMNI RESEARCH...

1. A method comprising mixing one or more types of monosaccharides, disaccharides, or a combination thereof with a water-deficient system at a temperature sufficient to form one or more types of prebiotic oligosaccharides, whereinthe weight ratio of monosaccharides, disaccharides, or a combination thereof to water-deficient system is 0.01 to 10; and the water-deficient system comprises a metal salt selected from an alkali metal salt and/or an alkaline earth metal salt, water, and a catalytic amount of acid wherein
the molar ratio of water to metal salt in the water-deficient system is about 2 to about 12; and
the acid has a pKa of less than 4.
US Pat. No. 10,711,278

GENETICALLY ALTERED ALFALFA PRODUCING CLOVAMIDE AND/OR RELATED HYDROXYCINNAMOYL AMIDES

The United States of Amer...

1. An expression cassette comprising a heterologous promoter operably linked to a cDNA, said cDNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, a sequence that is at least 95% identical to SEQ ID NO: 1, and a sequence that is at least 95% identical to SEQ ID NO: 3,wherein said cDNA encodes a protein with hydroxycinnamoyl-CoA:L-DOPA/tyrosine hydroxycinnamoyl transferase activity.
US Pat. No. 10,709,743

PHARMACEUTICAL WOUND HEALING COMPOSITION

1. A pharmaceutical composition for wound healing, comprising:a) 8% w/w of silk sericin;
b) 0.1% of sophorolipid;
c) 2-5% of a gelling or thickening agent; and
d) one or more pharmaceutically acceptable ingredients.
US Pat. No. 10,711,280

METHODS AND COMPOSITIONS FOR THE TARGETED MODIFICATION OF A MOUSE ES CELL GENOME

Regeneron Pharmaceuticals...

1. An in vitro method for modifying a genome at a genomic locus of interest in a mouse embryonic stem (ES) cell, comprising:introducing into the mouse ES cell a Cas9 protein or a nucleic acid encoding the Cas9 protein, a guide RNA or a DNA encoding the guide RNA, wherein the guide RNA comprises a CRISPR RNA that hybridizes to a CRISPR target sequence at the genomic locus of interest and a tracrRNA, and a large targeting vector (LTVEC) that is at least 10 kb in size and comprises an insert nucleic acid flanked by:
(i) a 5? homology arm that is homologous to a 5? target sequence at the genomic locus of interest; and
(ii) a 3? homology arm that is homologous to a 3? target sequence at the genomic locus of interest,
wherein the guide RNA is designed to avoid recognition of any sequence in the insert nucleic acid, and
wherein following introducing into the mouse ES cell the Cas9 protein or the nucleic acid encoding the Cas9 protein, the guide RNA or the DNA encoding the guide RNA, and the LTVEC, the genome of the mouse ES cell is modified to comprise a targeted genetic modification comprising (i) deletion of a region of the genomic locus of interest wherein the deletion is at least 30 kb and/or (ii) insertion of the insert nucleic acid at the genomic locus of interest wherein the insertion is at least 30 kb.
US Pat. No. 10,709,744

PROBIOTIC BIOFILM SUPPOSITORIES

MYBIOTICS PHARMA LTD., N...

1. A composition in the form of a suppository, comprising:(i) at least one viable probiotic bacteria in the form of dried biofilm;
(ii) a first agent comprising an antibiotic agent;
(iii) a first lipophilic carrier; and
optionally (iv) a pH adjusting agent,
wherein said at least one probiotic bacteria is 10% to 50% (w/w) of the total composition, and
wherein said at least one probiotic bacteria and said antibiotic agent are homogeneously dispersed within said first lipophilic carrier.
US Pat. No. 10,711,025

PROCESS FOR THE PREPARATION OF DIOSMIN

INTERQUIM, S.A., Barcelo...

1. Diosmin, or a pharmaceutically acceptable salt thereof, having a halogen content of more than 0 ppm to less than 1000 ppm and free from residual organic solvents.
US Pat. No. 10,711,281

ADENO-ASSOCIATED VIRAL (AAV) VECTORS USEFUL FOR TRANSDUCING ADIPOSE TISSUE

1. An adeno-associated viral (AAV) vector selected from the group consisting of AAV6, AAV7, AAV8 and AAV9, comprising a recombinant viral genome wherein said recombinant viral genome comprises AAV Inverted Terminal Repeats (ITRs) and an expression cassette comprising an adipose tissue-specific transcriptional regulatory region operatively linked to a polynucleotide of interest, said vector further comprising a capsid of AAV serotype 6, AAV serotype 7, AAV serotype 8 or AAV serotype 9, wherein said polynucleotide is specifically expressed in adipocytes of a mammal after administration of the vector to the mammal.
US Pat. No. 10,709,745

TROPIC CELL BASED VIROTHERAPY FOR THE TREATMENT OF CANCER

CITY OF HOPE, Duarte, CA...

1. A pharmaceutical composition for treating cancer, comprising a tropic cell that carries a modified oncolytic virus, wherein the virus comprises a tumor selective promoter element and/or a capsid protein that binds a tumor-specific cell surface molecule, and wherein the tropic cell is a stem cell from a neural stem cell line HB1.F3-CD.
US Pat. No. 10,711,282

OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF

Novartis AG, Basel (CH) ...

1. A lentiviral transfer vector comprising a heterologous nucleic acid sequence and being characterized by the following features:(a) comprising a cytomegalovirus (CMV) promoter,
(b) comprising a polynucleotide encoding at least a portion of a gag protein that comprises a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA relative to wild-type INS1,
(c) not comprising a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag, and
(d) not comprising an SV40 origin of replication and/or an f1 origin of replication.
US Pat. No. 10,709,746

COMPOSITIONS AND METHODS FOR TREATING MEMORY LOSS AND DIMINISHED COGNITION

1. A composition for treating memory loss and diminished cognition, comprising:a) about 100 mg to about 1000 mg of Hericium erinaceus;
b) about 50 mg to about 650 mg of Bacopa monnieri;
c) about 10 mg to about 200 mg of epigallocatechin gallate (EGCG);
d) about 25 mcg to about 400 mcg of Huperzine;
e) about 100 mg to about 1,000 mg of Acetyl-L-Carnitine;
f) about 50 mcg to about 1,000 mcg of Vitamin B12; and
g) a blend, comprising:
(i) about 10 mg to about 160 mg of Ginkgo biloba;
(ii) about 10 mg to about 400 mg of Phosphatidylserine; and
(iii) about 10 mg to about 500 mg of Gotu Kola.
US Pat. No. 10,710,002

METHOD OF EXTRACTING NUTRIENTS FROM A PLANT

NUECOLOGY BIOMEDICAL INC....

1. A method of extracting nutrients from a plant, comprising:(a) pulverizing a first plant material of the plant so as to obtain a first pulverized plant part containing a water-soluble nutrient and a plant juice;
(b) pulverizing a second plant material so as to obtain a second pulverized plant part containing a lipid-soluble nutrient;
(c) subjecting the first pulverized plant part to a fractional distillation under an increasing temperature gradient at a pressure in a range from 0.01 kPa to 202.2 kPa to obtain a liquid distillate fraction and a first residue that contains a water-soluble nutrient,
wherein the distillate includes three separated distillate fractions: a first distillate fraction collected at a temperature of lower than 50° C., a second distillate fraction collected at a temperature ranging from 50° C. to 70° C., and a third distillate fraction collected at a temperature ranging from 70° C. to 90° C.; and
(d) immersing the second pulverized plant part in a liquid distillate fraction at a temperature in a range from 5° C. to 75° C. for 1 hour to 48 hours to form a mixture followed by distilling the mixture at a temperature in a range from 40° C. to 90° C. for 0.5 hours to 10 hours to obtain a second residue that is a second extract that contains the lipid-soluble nutrient,
wherein the water-soluble nutrient is selected from the group consisting of vitamin C, ?-aminobutyric acid, salvianolic acid, norbixin, catechin, citric acid, anthocyanidin, and combinations thereof, and
wherein the lipid-soluble nutrient is selected from the group consisting of vitamin E, curcumin, tashinone, phytosterol, chlorophyll, and combinations thereof.
US Pat. No. 10,711,283

PRIMARY CELL GENE EDITING

PACT PHARMA, INC., South...

1. A composition comprising a polynucleotide, wherein the polynucleotide comprises:a. first and second homology arms homologous to first and second target nucleic acid sequences;
b. a TCR gene sequence positioned between the first and second homology arms;
c. a first P2A-coding sequence positioned upstream of the TCR gene sequence and a second P2A-coding sequence positioned downstream of the TCR gene sequence, wherein the first and second P2A-coding sequences code for the same amino acid sequence that are codon-diverged relative to each other;
d. a sequence coding for the amino acid sequence Gly Ser Gly positioned immediately upstream of the P2A-coding sequences; and
e. a sequence coding for a Furin cleavage site positioned upstream of the second P2A-coding sequence.
US Pat. No. 10,709,747

ENCAPSULATED CANNABINOID FORMULATIONS FOR ORAL DELIVERY

NUTRAE, LLC, Sarasota, F...

1. A cannabinoid composition for oral delivery, said composition comprising:a cannabinoid preparation ranging from 0.001% to 3% (w/w);
at least one surfactant ranging from 2% to 15% (w/w);
at least one co-solvent ranging from 20% to 65% (w/w);
at least one flavoring composition ranging from 0.1% to 5% (w/w);
a preservative ranging from 0.01% to 5% (w/w); and
water ranging from 2% to 77% (w/w);wherein said preparation is encapsulated by surfactants to form micelles having uni-, bi-, or multi-lamellar structures and yields the cannabinoid preparation capable of having increased bioavailability and operable for oral delivery.
US Pat. No. 10,711,284

CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING

THE REGENTS OF THE UNIVER...

1. A single vector comprising at least one synthetic oligonucleotide, wherein the at least one synthetic oligonucleotide comprises the following covalently-linked components: (i) two nucleic acids each encoding a gRNA sequence targeting a target region in a cell; (ii) a region homologous to the target region comprising a change in sequence relative to the target region; and (iii) a site conferring immunity to nuclease-mediated editing.
US Pat. No. 10,709,748

ENCAPSULATED CANNABINOID FORMULATIONS FOR TRANSDERMAL DELIVERY

NUTRAE, LLC, Sarasota, F...

1. A cannabinoid composition capable of trans canal delivery, comprising:a cannabinoid composition further comprising:
a cannabinoid preparation ranging from 0.1% to 20% (w/w);
at least one surfactant ranging from 5% to 50% (w/w);
at least one co-solvent ranging from 10% to 70% (w/w);
water ranging from 16% to 60% (w/w); and
wherein the cannabinoid composition is capable of topical application and wherein the cannabinoid preparation is encapsulated by surfactants to form micelles having uni-, bi-, or multi-lamellar structures.
US Pat. No. 10,710,004

WASTE STREAM UPGRADING IN A PROPYLENE OXIDE/STYRENE COPRODUCTION PROCESS

Lyondell Chemical Technol...

1. A method comprising:(a) conducting a production to produce an effluent comprising propylene oxide and styrene;
(b) recovering a heavy residue stream from the effluent comprising propylene oxide and styrene;
(c) contacting water and carbon dioxide with the heavy residue stream to produce a mixture, wherein the mixture comprises an organic phase and an aqueous phase,
(d) separating the organic phase and the aqueous phase, thereby producing an organic stream and an aqueous stream, whereby sodium is extracted from the organic stream; and
wherein the aqueous stream comprises an aqueous sodium salt-containing slurry phase from the organic phase comprising a reduced sodium content relative to the organic stream.
US Pat. No. 10,711,285

OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION

THE BROAD INSTITUTE, INC....

1. A method of modifying a genomic locus of interest including minimizing off-target modifications, comprising introducing into a eukaryotic cell containing a double stranded DNA molecule, an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas9 protein having one or more mutations wherein the one or more mutations is in a RuvC or HNH domain and two guide RNAs that target a first strand and a second strand of the DNA molecule respectively, whereby the Cas9 protein nicks each of the first strand and the second strand of the DNA molecule; wherein the Cas9 protein and the two guide RNAs do not naturally occur together; wherein the Cas9 protein nicking each of the first strand and the second strand of the DNA molecule results in at least one 5? overhang of at least 26 nucleotides.
US Pat. No. 10,709,750

FEMALE MENOPAUSE ALLEVIATION USE OF COMPOSITION CONTAINING COMPOSITE EXTRACT OF RED CLOVER AND POMEGRANATE AS ACTIVE INGREDIENT

Hae-Yeon LEE, Gyeonggi-D...

1. A method for reducing a menopausal disorder, comprising: administering a composition comprising a composite of pomegranate extract and red clover extract as an active ingredient to a subject in need thereof;wherein the weight ratio of the pomegranate extract to the red clover extract is 1:1-4
wherein the red clover extract comprises 50-150 mg/g of isoflavone in relation to total red clover extract, and
wherein the composite of pomegranate extract and red clover extract comprises 30-100 mg/g of isoflavone and 0.15-0.4 mg/g of ellagic acid.
US Pat. No. 10,711,031

METHOD FOR EXTRACTING PHYTOSTEROLS FROM TALL OIL PITCH

ORGKHIM BCH MANAGEMENT CO...

1. A method for extracting phytosterols from tall oil pitch, the method consisting of saponifying tall oil pitch with an alkali in a polyatomic alcohol, extracting unsaponified matter from the alkali-alcohol solution using a hydrocarbon solvent, subsequently removing the solvent by distillation, and concentrating the phytosterols, wherein a mixture of paraffin hydrocarbons with 8 to 17 carbon atoms is used as the hydrocarbon solvent, and, following the extraction, botulin is isolated from the extract solution by crystallization at a temperature of 50 to 83° C. and the phytosterols are then concentrated by means of rectification.
US Pat. No. 10,711,287

D-LACTATE DEHYDROGENASE, ENGINEERED STRAIN CONTAINING D-LACTATE DEHYDROGENASE AND CONSTRUCTION METHOD AND USE OF ENGINEERED STRAIN

Shanghai Jiao Tong Univer...

1. A D-lactate dehydrogenase comprising a substitution, deletion, insertion, addition of one or more amino acid residues, wherein said D-lactate dehydrogenase comprises an amino acid sequence having at least 80% and less than 100% sequence identity to SEQ ID NO: 1, and wherein said D-lactate dehydrogenase has D-lactate dehydrogenase activity.
US Pat. No. 10,709,751

CHARDONNAY GRAPE SEED EXTRACT

SHAKLEE CORPORATION, Ple...

1. A composition comprising an effective amount of a water extract of Chardonnay grape seed and a pharmaceutically acceptable carrier, wherein the extract consists essentially of Fraction B or C which comprise by percentage dry weight:Fraction B:
38-50% Polyphenols,
9-12% Fiber,
1-2% Protein,
<1% Lipids,
25-30% Sugars; and
Fraction C:
45-55% Polyphenols,
26-30% Fiber,
2-3% Proteins,
<1% Lipids,
<1% Sugars;
wherein the extract is obtained by the steps of:
(a) mixing washed grape seeds with heated water at a temperature below 100° C.
US Pat. No. 10,711,288

METHODS OF PRODUCING OMEGA-HYDROXYLATED FATTY ACID DERIVATIVES

GENOMATICA, INC., San Di...

1. A recombinant microorganism engineered to express a CYP153A-reductase hybrid fusion polypeptide variant comprising a CYP153A ?-hydroxylase domain and a P450RhF reductase domain; wherein the hybrid fusion polypeptide variant has at least 91% sequence identity to SEQ ID NO: 6 and has one or more mutations selected from the group consisting of V141I, V141T, V141Q, V141G, V141M, V141L, R27L, R82D, R178N, A231T, N309R, N407A, V415R, T516V, P666A, P666D and A796V.
US Pat. No. 10,711,289

METHOD OF PRODUCING AND PROCESSING DIAMINES FROM AN ENGINEERED MICROORGANISM

GENOMATICA, INC., San Di...

1. A process for diamine (DA) production comprising the steps of:a) culturing a genetically engineered microorganism comprising a diamine (DA) synthesis pathway selected from the group consisting of hexamethylenediamine, cadaverine, putrescine, ethylenediamine and heptamethylenediamine with at least one exogenous nucleic acid encoding at least one enzyme of the DA synthesis pathway for producing a DA in medium under suitable conditions and for a sufficient period of time to produce DA and form one or more of DA carbonate, DA bicarbonate, and/or DA bis-bicarbonate in a cultured medium and a carbonic anhydrase in sufficient amount to (a) enhance the formation of the DA carbonate, DA bicarbonate, and/or, DA bis-bicarbonate by converting carbon dioxide to a bicarbonate and/or carbonate ions, (b) enhance the release of carbon dioxide from a solution of DA carbonate, DA bicarbonate, and/or DA bis-bicarbonate by converting a bicarbonate and/or carbonate ions to carbon dioxide, or (c) both (a) and (b);
wherein
i) carbon dioxide, carbonate, bicarbonate or carbonic acid predominantly control pH of the medium;
ii) percent dissolved inorganic carbon (DIC) in the medium is greater than or equal to 40%; and the DIC is determined by the formula:
DIC/TDCA×100
where TDCA is the Total Dissolved Counter Anions and is the sum of DIC and other anions; or
iii) at least 40% of diamine species in the medium comprises one or more of DA carbonate, DA bicarbonate, and/or DA bis-bicarbonate;
b) converting at least one or more of the DA carbonate, DA bicarbonate, and/or DA bis-bicarbonate into DA free base and carbon dioxide; and
c) isolating the DA free base.
US Pat. No. 10,711,034

INTEGRATED CONTINUOUS MANUFACTURING OF THERAPEUTIC PROTEIN DRUG SUBSTANCES

Genzyme Corporation, Cam...

1. A process for manufacturing a drug substance comprising a recombinant ?-galactosidase-A, the process comprising:(a) culturing cells in a perfusion bioreactor comprising a liquid culture medium under conditions that allow the cells to secrete the recombinant ?-galactosidase-A into the medium, wherein at least 90% cell-free volumes of the medium are continuously or periodically removed from the perfusion bioreactor and fed into a periodic counter current chromatography system (PCCS);
(b) capturing the recombinant ?-galactosidase-A from the medium using a hydrophobic interaction and anion exchange resin in the PCCS; and
(c) further purifying and polishing the recombinant ?-galactosidase-A by performing, sequentially, hydrophobic interaction chromatography, viral inactivation, cation exchange chromatography, and affinity chromatography, to yield the drug substance.
US Pat. No. 10,709,754

COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING HYPERURICEMIA OR METABOLIC DISORDERS RELATED WITH HYPERURICEMIA COMPRISING EXTRACT OF ALPINIA OXYPHYLLA AS EFFECTIVE INGREDIENT

KOREA INSTITUTE OF ORIENT...

1. A method for treating hyperuricemia or a metabolic disorder related with hyperuricemia, the method comprising administering to a subject in need thereof a composition comprising an extract of Alpinia oxyphylla as an effective ingredient,wherein the extract of Alpinia oxyphylla is extracted by using ethanol as a solvent.
US Pat. No. 10,711,035

SEPARATION MATRIX

1. A separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein:a) said ligands comprise multimers of alkali-stabilized Protein A domains, and
b) said porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml,
wherein the separation matrix has a 10% breakthrough dynamic binding capacity for IgG of at least 45 mg/ml at 2.4 min residence time.
US Pat. No. 10,711,291

RECOMBINANT ENGINEERED BACTERIUM CO-EXPRESSING TRANS-ANETHOLE OXYGENASE AND FORMATE DEHYDROGENASE AND APPLICATION THEREOF IN PRODUCTION OF PIPERONAL

Jiangnan University, Wux...

1. A recombinant engineered bacterium for producing piperonal, which comprises:a gene encoding a trans-anethole oxygenase mutant having the nucleotide sequence of SEQ ID NO: 3, and a gene encoding a formate dehydrogenase that when expressed oxidizes formate;
wherein the gene encoding the formate dehydrogenase and the gene encoding the trans-anethole oxygenase mutant are connected in series in a bacterial expression vector.
US Pat. No. 10,709,755

SOLID FORMULATION AND METHOD FOR PREVENTING OR REDUCING COLORATION THEREOF

1. A solid formulation characterized by comprising:(A) 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-1?-phenyl-1?-[N?-(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine, or a pharmaceutically acceptable salt, solvate, or solvate of such a salt, wherein the solid formulation comprises:
one core, wherein said core is a homogenous mixture comprising ingredient (A), and
one coating layer or capsule layer enclosing at least a part of said core, wherein said coating layer or capsule layer comprises (C) polyvinyl alcohol and does not comprise (b) polyethylene glycol
wherein said coating layer or capsule layer comprises said ingredient (C) in an amount ranging from 50 to 90% by weight based on the total weight of the coating layer or capsule layer.
US Pat. No. 10,711,292

METHOD FOR PROMOTING THE SYNTHESIS OF COLLAGEN AND PROTEOGLYCAN IN CHONDROCYTES

NIKKON ZOKI PHARMACEUTICA...

1. A method for determining or evaluating the promoting effect of an extract isolated from a rabbit skin inflamed by inoculation with vaccinia virus on synthesis of proteoglycan and/or collagen comprising:a) treating cultured nucleus pulposus cells under hypoxic conditions with an effective amount of the extract to promote synthesis of proteoglycan in the cultured nucleus pulposus cells, and measuring a promoting activity on the synthesis of proteoglycan in the cultured nucleus pulposus cells by said extract, or
b) treating cultured nucleus pulposus cells and/or cultured anulus fibrosus cells under normoxic conditions with an effective amount of the extract to promote synthesis of collagen in the cultured nucleus pulposus cells and/or anulus fibrosus cells, and measuring a promoting activity on the synthesis of collagen in the cultured nucleus pulposus cells and/or anulus fibrosus cells by said extract, or
c) treating cultured nucleus pulposus cells under hypoxic conditions with an effective amount of the extract to promote synthesis of collagen in the cultured nucleus pulposus cells, and measuring a promoting activity on the synthesis of collagen in the cultured nucleus pulposus cells by said extract.
US Pat. No. 10,711,293

METHODS FOR DISTINGUISHING AND IDENTIFYING PLANT VARIETIES

Syngenta Participations A...

1. A method of distinguishing a first transgenic maize plant from a second maize plant, the method comprising the steps of:a. heating a solution of a milled transgenic maize plant part from a first transgenic maize plant comprising event 3272 expressing a heterologous thermotolerant 797GL3 alpha-amylase enzyme to a temperature above a gelatinization temperature of starch, wherein the temperature is between about 60° C. to about 100° C.;
b. continuously measuring viscosity changes of the solution for a time period of about 10 seconds to about 2 minutes, which results in only partial hydrolysis of starch;
c. obtaining a viscosity curve for the first transgenic maize plant based on the measurements of step (b); and
d. comparing the viscosity curve from the first transgenic maize plant to a viscosity curve obtained in the same manner from a second maize plant, wherein differences in the slopes of the viscosity curves distinguish the first transgenic maize plant from the second maize plant.
US Pat. No. 10,711,038

AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS

Bausch Health Ireland Lim...

1. A method for treating Irritable Bowel Syndrome (IBS) comprising:administering daily orally to a patient an effective dosage of a guanylate cyclase receptor agonist having the amino acid sequence of SEQ ID NO:1, wherein said agonist is a [4,12;7,15] bicyclic peptide, and
administering to said patient an effective dose of a cGMP-dependent phosphodiesterase inhibitor comprising sulindac sulfone or zaprinast, either concurrently or sequentially with said agonist.
US Pat. No. 10,709,758

PEPTIDE INHIBITORS OF CLOSTRIDIUM DIFFICILE TOXIN B (TCDB) TOXIN

The Board of Regents of t...

1. A pharmaceutical composition, comprising:a peptide disposed in a pharmaceutically-acceptable carrier or vehicle, the peptide comprising an amino acid sequence X1 X2 X3 X4 X5 X6 X7 X8 X9 X10 X11 (SEQ ID NO:67), wherein
each of X1, X2, X3, X4, X7, X8, X9, X10, and X11 is independently selected from the group consisting of gly, L-ala, L-arg, L-asn, L-asp, L-cys, L-glu, L-gln, L-his, L-ile, L-leu, L-lys, L-met, L-phe, L-pro, L-ser, L-thr, L-trp, L-tyr, L-val, D-ala, D-arg, D-asn, D-asp, D-cys, D-glu, D-gln, D-his, D-ile, D-leu, D-lys, D-met, D-phe, D-pro, D-ser, D-thr, D-trp, D-tyr, and D-val;
X5 is selected from gly, L-ala, L-ser, D-ala, and D-ser;
X6 is selected from L-asn, L-asp, L-gln, L-his, L-ser, L-thr, D-asn, D-asp, D-gln, D-his, D-ser, and D-thr; and
wherein the amino acid sequence SEQ ID NO:67 has at least 90% identity with SEQ ID NO:1, has a length of from 15 to 100 amino acids, and has anti-Clostridium difficile toxin B activity and/or has cell penetrating activity.
US Pat. No. 10,711,295

COMPOSITIONS, KITS AND RELATED METHODS FOR THE DETECTION AND/OR MONITORING OF SALMONELLA

Gen-Probe Incorporated, ...

16. A method for detecting Salmonella in a sample, said method comprising a detecting step of detecting the presence or absence of a Salmonella target nucleic acid using the detection oligonucleotide of claim 1.
US Pat. No. 10,709,759

SELF-REPLICATING CELL SELECTIVE GENE DELIVERY COMPOSITIONS, METHODS, AND USES THEREOF

University of South Flori...

1. A polyribonucleotide comprising:an RNA molecule of interest (ROI), wherein the ROI comprises a nucleic acid sequence encoding a protein, wherein the protein comprises BAX, PTEN, p16, P15, P18, P19, P21, P57 or CDKN3;
a microRNA (miRNA) target sequence operatively linked to the ROI, wherein the miRNA target sequence is a target for miR-126, miR-122, miR-208, miR-145, or miR-143; and
an RNA molecule comprising a nucleic acid sequence encoding a viral RNA replicase operatively linked to the ROI, the miRNA target sequence, or both the ROI and miRNA target sequence.
US Pat. No. 10,709,760

TREATMENT OF CHRONIC ULCERS

Promore Pharma AB, Solna...

1. A method of treating a chronic ulcer, wherein said method comprises:(a) topically applying to said chronic ulcer a pharmaceutical formulation, wherein the pharmaceutical formulation is an aqueous solution comprising LL-37 or a pharmaceutically-acceptable salt thereof, wherein the pharmaceutical formulation comprises one thickening agent; followed by
(b) topically applying a dressing to said chronic ulcer;
wherein the dose of LL-37 applied per cm2 of wound area is between about 1 ?g/cm2 and about 70 ?g/cm2, and wherein the pharmaceutical formulation has a viscosity in the range of about 2 and about 10 Pa·s.
US Pat. No. 10,711,041

LYOPHILISATE CONTAINING A CYCLIC PEPTIDE OF FORMULA X1-GQRETPEGAEAKPWY-X2

APEPTICO FORSCHUNG UND EN...


wherein
X1 comprises an amino acid sequence, with 1 to 4 members, comprising natural and unnatural amino acids, and
X2 comprises a natural amino acid, and wherein
X1 comprises the N-terminal amino acid in position 1 on the left in formula I, and X2 comprises the C-terminal amino acid in the ultimate, right position in formula I,
wherein the cyclic peptide is in the form of a lyophilisate prior to mixing with the water,
wherein the aqueous aerosol includes particles of the water and the cyclic peptide, the particles having a diameter less than or equal to 5 ?m,
wherein the cyclic peptide, when in solution, remains fully active for a period of at least 7 days, and
wherein the cyclic peptide, when in a lyophilized form, remains fully active at room temperature for a period of at least 6 months.
US Pat. No. 10,711,297

AUTOMATED METHOD FOR ANALYZING SAMPLES

Gen-Probe Incorporated, ...

1. An automated method for analyzing a plurality of samples, the method comprising performing within a housing of a self-contained system the steps of:(a) loading the system with the plurality of samples;
(b) after step (a), performing a first assay on a first sample subset of the plurality of samples, the first assay comprising:
(i) exposing each sample of a first sample subset to a first target capture reagent comprising a solid support for directly or indirectly immobilizing a first target nucleic acid that may be present in one or more samples of the first sample subset; and
(ii) after step (b)(i), performing in each sample of the first sample subset a first amplification reaction for amplifying a region of the first target nucleic acid; and
(c) after step (a), performing a second assay on a second sample subset of the plurality of samples, the second assay comprising:
(i) exposing each sample of the second sample subset to a second target capture reagent comprising a solid support for directly or indirectly immobilizing a second target nucleic acid that may be present in one or more samples of the second sample subset; and
(ii) after step (c)(i), performing in each sample of the second sample subset a second amplification reaction for amplifying a region of the second target nucleic acid,
wherein for each sample of the first sample subset, step (b)(i) is performed in a first receptacle and step (b)(ii) is performed in a second receptacle, the first and second receptacles having different configurations, and
wherein for each sample of the second sample subset, steps (c)(i) and (c)(ii) are performed in a third receptacle, the first and third receptacles having the same configuration.
US Pat. No. 10,709,761

METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING CANCER

UNIVERSITY OF UTAH RESEAR...

1. A method of inhibiting human cancer, which comprises contacting a human cancer cell with(a) one or more nucleic acids each having a sequence encoding an elephant p53 protein, selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 20 and combinations thereof, or
(b) one or more elephant p53 proteins each having a sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 13, SEQ ID NO: 21 and combinations thereof, whereby the human cancer is inhibited by causing the human cancer cell to undergo apoptosis.
US Pat. No. 10,711,042

STABILIZED VIRAL CLASS I FUSION PROTEINS

1. A method for treating a viral infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a pre-fusion class I fusion protein or a nucleic acid molecule encoding the pre-fusion class I fusion protein, wherein the pre-fusion class I fusion protein comprises one or more mutations in the hinge-loop that is present between the base helix and the RR1, wherein the one or more mutations comprise a mutation of one or more hydrophobic amino acid residues into Pro, and wherein the class I fusion protein is a Filovirus fusion F protein, a retroviral envelope protein, or an influenza hemagglutinin (HA) protein.
US Pat. No. 10,711,298

OLIGONUCLEOTIDE DETECTION METHOD

AXOLABS GMBH, Kulmbach (...

1. A method for detecting a target therapeutic RNA oligonucleotide having a pre-defined sequence and RNA oligonucleotide metabolites of said target therapeutic RNA oligonucleotide, comprising the steps of:(a) preparing a sample containing or suspected of containing said target therapeutic RNA oligonucleotide having said pre-defined sequence and said RNA oligonucleotide metabolites of said target therapeutic RNA oligonucleotide, wherein said target therapeutic RNA oligonucleotide has a length of 10 nucleotides up to 29 nucleotides, and wherein said RNA oligonucleotide metabolites are said target therapeutic RNA oligonucleotide from which 1 or more nucleotides have been deleted from the 3?- and/or the 5?-end, and/or said RNA oligonucleotide metabolites are said target therapeutic RNA oligonucleotide comprising phosphorylated 3?- or 5?-ends, and wherein said sample is an extracellular or intracellular sample,
(b) forming a hybridization mixture by contacting the sample with a fluorescently labeled peptide nucleic acid (PNA) probe,
(c) hybridizing the PNA probe to said target therapeutic RNA oligonucleotide having said pre-defined sequence and hybridizing the PNA probe to said RNA oligonucleotide metabolites of said target therapeutic RNA oligonucleotide, wherein said PNA probe and said target therapeutic RNA oligonucleotide having said pre-defined sequence are fully complementary over at least 10 nucleotides of said target therapeutic RNA oligonucleotide having the pre-defined sequence,
(d) separating hybridized moieties formed between said PNA probe and said target therapeutic RNA oligonucleotide having said pre-defined sequence, and hybridized moieties formed between PNA probe and said RNA oligonucleotide metabolites of said target therapeutic RNA oligonucleotide, from unhybridized moieties by anion exchange high performance liquid chromatography (HPLC), wherein signals associated with said hybridized moieties formed between said PNA probe and said RNA oligonucleotide metabolites of said target therapeutic RNA oligonucleotide are separated from a signal associated with hybridized moieties formed between said PNA probe and said target therapeutic RNA oligonucleotide, and
(e) detecting quantitatively in a single fluorescence spectroscopy measurement said hybridized moieties formed between said PNA probe and said target therapeutic RNA oligonucleotide having said pre-defined sequence and hybridized moieties formed between said PNA probe and said RNA oligonucleotide metabolites of said target therapeutic RNA oligonucleotide.
US Pat. No. 10,712,322

IONIC STRENGTH-MEDIATED PH GRADIENT ION EXCHANGE CHROMATOGRAPHY

Genentech, Inc., South S...

1. A method for analyzing a composition comprising a polypeptide and one or more charge variants of the polypeptide, the method comprisinga) binding the polypeptide and one of more charge variants of the polypeptide to an ion-exchange chromatography material using a loading buffer, wherein the loading buffer is at a first pH and comprises a first ionic strength;
b) eluting the polypeptide and one or more charge variants of the polypeptide from the ion-exchange chromatography material using an elution buffer wherein the pH of the elution buffer is altered in a pH gradient and the ionic strength of the elution buffer is altered in an ionic strength gradient, wherein the polypeptide and the one or more charge variants of the polypeptide are separated by the combination of pH gradient and ionic strength gradient; and
c) detecting the polypeptide and the one or more charge variants of the polypeptide wherein the polypeptide has a pI greater than about 9.0 or less than about 7.0.
US Pat. No. 10,709,762

USE OF M-CSF FOR PREVENTING OR TREATING MYELOID CYTOPENIA AND RELATED COMPLICATIONS

INSERM (INSTITUT NATIONAL...

1. A method of treating myeloid cytopenia and an associated viral, bacterial and/or fungal infection in a patient in need thereof, comprising:increasing production of myeloid cells expressing transcription factor PU.1 in said patient by administering to said patient a therapeutically effective amount of a macrophage colony stimulating factor (M-CSF) polypeptide or an interleukin-34 polypeptide, wherein said patient is undergoing or has undergone hematopoietic stem cell transplantation (HSCT), wherein expression of MafB in cells of a stem cell graft used for the HSCT was not previously modified, and wherein said myeloid cytopenia is neutropenia, monocytopenia and/or cytopenia of monocyte derived mononuclear phagocytes, wherein said myeloid cells comprise granulocyte/monocyte progenitor cells that give rise to granulocytes, monocytes and macrophages.
US Pat. No. 10,711,299

PULSE CALLER AND BASE CALLER

Quantum-Si Incorporated, ...

1. A sequencing instrument, comprising:a photodetector configured to receive light from luminescent labels during nucleotide incorporation events of a sequencing reaction, the luminescent labels being associated with nucleotides; and
a processor configured to:
obtain characteristics of the light, the characteristics including, for individual nucleotide incorporation events,
a temporal characteristic of the light, the temporal characteristic representing a speed of decay of a probability of photon emission by a luminescent label after excitation; and
an intensity characteristic of the light, wherein the temporal characteristic and the intensity characteristic are characteristics of light received from a luminescent label during a nucleotide incorporation event; and
wherein the temporal characteristic and the intensity characteristic are used to perform one or more of: identifying individual nucleotides, and calibrating the sequencing instrument, and
wherein the intensity characteristic represents a quantity of photogenerated charge carriers produced over time by the photodetector from the light received from the luminescent label during the nucleotide incorporation event.
US Pat. No. 10,709,763

GPCR HETEROMER INHIBITORS AND USES THEREOF

GPCR THERAPEUTICS, INC., ...

1. A method of inhibiting cancer progression in a cancer patient having a CXCR4-ADRB2 heteromer in a cancer cell, the method comprising:determining whether the cancer patient's cancer cell contains the CXCR4-ADRB2 heteromer;
if the CXCR4-ADRB2 heteromer is present in the cancer patient's cancer cell, then administering to said cancer patient having said CXCR4-ADRB2 in said cancer cell an inhibitor of CXCR4 and an inhibitor of ADRB2;wherein:i) the CXCR4-ADRB2 heteromer has an enhanced amount of downstream calcium mobilization relative to downstream calcium mobilization from a CXCR4 protomer or ADRB2 protomer;
ii) the administered combination of inhibitors suppresses the enhanced downstream calcium mobilization from said CXCR4-ADRB2 heteromer in the cell;
iii) the CXCR4 inhibitor is selected from the group consisting of: AD-114, AD-114-6H, AD-114-Im7-FH, AD-114-PA600-6H, ALX-0651, ALX40-4C, AMD070 (AMD11070, X4P-001), AMD3100 (plerixafor), AMD3465, ATI 2341, BKT140 (BL-8040; TF14016; 4F-Benzoyl-TN14003), CTCE-9908, CX549, D-[Lys3] GHRP-6, FC122, FC131, GMI-1359, GSK812397, GST-NT21MP, isothiourea-1a, isothiourea-1t (IT1t), KRH-1636, KRH-3955, LY2510924, LY2624587, MSX-122, N-[11C]Methyl-AMD3465, PF-06747143, POL6326, SDF-1 1-9[P2G] dimer, SDF1 P2G, T134, T140, T22, TC 14012, TG-0054 (Burixafor), USL311, ulocuplumab (MDX1338/BMS-936564), viral macrophage inflammatory protein-II (vMIP-II), WZ811, 12G5, 238D2, 238D4, [64Cu]-AMD3100, [64Cu]-AMD3465, [68Ga]pentixafor, [90Y]pentixather, [99mTc]O2-AMD3100, [177Lu]pentixather, and 508MCl (Compound 26); and
iv) the ADRB2 inhibitor is selected from the group consisting of: Alprenolol, atenolol, betaxolol, bupranolol, butoxamine, carazolol, carvedilol, CGP 12177, cicloprolol, ICI 118551, ICYP, labetalol, levobetaxolol, levobunolol, LK 204-545, metoprolol, nadolol, NIHP, NIP, propafenone, propranolol, sotalol, SR59230A, and timolol.
US Pat. No. 10,711,044

CHANNELRHODOPSINS FOR OPTICAL CONTROL OF CELLS

Massachusetts Institute o...

1. A recombinant nucleic acid vector comprising a heterologous nucleic acid molecule insert encoding a light-activated ion channel amino acid polypeptide sequence, the amino acid sequence having at least 90% amino acid identity to amino acids 86-320 as set forth in SEQ ID NO: 2 and at least 95% identity to the amino acids 321-350 as set forth as SEQ ID NO: 2.
US Pat. No. 10,711,045

ISOLATION OF NUCLEOSOMES HAVING MULTIPLE-MODIFIED HISTONE PROTEIN OCTAMERS

1. An in-vitro method for isolating a nucleosome having a first and a second histone modification, the method comprising the steps of:(a) providing an artificial protein, wherein the artificial protein comprises
a first histone modification binding domain of 50 to 200 amino acids binding to the first histone modification,
a second histone modification binding domain of 50 to 200 amino acids binding to the second histone modification,
a linker of 5 to 50 amino acids connecting the first and the second histone modification binding domain, and
an affinity tag,
wherein the first histone modification binding domain is the PWWP domain of Dnmt3a and the second histone modification binding domain is the chromodomain of MPP8,
(b) contacting the artificial protein with a sample comprising nucleosomes to allow formation of a complex of the artificial protein and a nucleosome having the first and the second histone modification; and
(c) isolating the complex.
US Pat. No. 10,711,301

PREDICTING RESISTANCE TO DISEASE

AquaGen AS, Trondheim (N...


US Pat. No. 10,710,278

METHOD FOR PRODUCING AN ELASTOMERIC SKIN HAVING A GRAINED SURFACE

1. A method for producing an elastomeric skin, wherein said skin has at least a portion which has a grained surface having valleys and peaks, which comprises at least one elastomeric skin layer and which has at least one coating layer overlying the skin layer, which method comprises the steps of:applying a low viscosity coating composition, comprising effect pigment particles contained in a transparent or translucent medium, onto at least a portion of a mould surface, which portion is grained by having valleys and peaks to produce said coating layer, said mould surface having a grain depth and said coating layer having an average dry thickness which is smaller than said grain depth; and
moulding said elastomeric skin layer at least against a back side of said coating layer to produce said portion of the elastomeric skin,
wherein said low viscosity coating composition has a viscosity of less than 800 centistoke at the temperature of the mould surface and is a liquid coating composition or is liquefied when being applied and said coating layer of said portion of the elastomeric skin has a thickness that is smaller in the valleys of said portion of the elastomeric skin than in the peaks of said portion of the elastomeric skin.
US Pat. No. 10,711,046

METHOD FOR ESTABLISHING EUKARYOTIC EXPRESSION CELL LINE OF CD36 MUTANT GENE THAT ENCODES CD36 DEFICIENCY

NAN-NING INSTITUTE OF TRA...

1. A method for establishing eukaryotic expression cell line of CD36 mutant gene that encodes CD36 deficiency, the method comprising:(1) extracting total RNA from a whole blood sample derived from a CD36-deficient individual, and amplifying a coding sequence (CDS) in CD36 mRNA in the total RNA by Reverse Transcription PCR (RT-PCR) using a pair of primers, to obtain a cDNA sequence fragment of the mutant CD36 gene (MT-CD36 cDNA), wherein the pair of primers comprise an upstream primer YC-36F having a sequence of SEQ ID NO: 1, and a downstream primer YC-36R having a sequence of SEQ ID NO: 2;
2) using the MT-CD36 cDNA obtained in (1) as a template, a forward primer CD36-F2, and a reverse primer CD36-R3 to PCR-amplify a target sequence of MT-CD36-EGFP-1 comprising an EcoR 1 cleavage site and protective bases, a full-length coding sequence (CDS) excluding the terminator of CD36 cDNA, a fusion gene BamH I and protective bases, and a portion of a 5?-terminal sequence of an EGFP fluorescent reporter gene, wherein the forward primer CD36-F2 has a sequence of SEQ ID NO: 3, and the reverse primer CD36-R3 has a sequence of SEQ ID NO: 4;
using a eukaryotic plasmid pEGFP-N1 comprising the EGFP fluorescent reporter gene as a template, a forward primer EGFP-F4, and a reverse primer EGFP-R2 to PCR-amplify a target sequence of MT-CD36-EGFP-2 comprising a portion of the 3?-terminal fragment of the CD36 CDS cDNA, the fusion gene BamH I and protective bases, a full-length of the EGFP fluorescent reporter gene, and an XhoI cleavage site and protective bases, wherein the forward primer EGFP-F4 has a sequence of SEQ ID NO: 5, and the reverse primer EGFP-R2 has a sequence of SEQ ID NO: 6; and
performing Gene Splicing by Overlap Extension PCR (SOE-PCR) using the MT-CD36-EGFP-1 and MT-CD36-EGFP-2 as templates and CD36-F2 and EGFP-R2 as primers to obtain a mutant gene sequence of MT-CD36-EGFP;
(3) constructing and amplifying a MT-CD36-EGFP-pLV4/StripII-HIS10 eukaryotic expression vector by ligating the MT-CD36-EGFP of (2) to a pLV4/StripII-HIS10 vector; the MT-CD36-EGFP-pLV4/StripII-HIS10 eukaryotic expression vector comprising the full-length CDS excluding the terminator of the mutant CD36 cDNA and the EGFP fluorescent gene; and
(4) transfecting the MT-CD36-EGFP-pLV4/StripII-HIS10 eukaryotic expression vector into a CHO-K1 cell line by using virus-mediated transfection of eukaryotic cells, and screening and constructing a eukaryotic cell line MT-CD36-CHO-K1 expressing the mutant CD36 gene that encodes CD36 deficiency.
US Pat. No. 10,709,766

FUSION PROTEINS

Eli Lilly and Company, I...


 wherein X1 is T or I; X2 is D, Y, Q or E; X3 is G, N, S or A; and X4 is any naturally occurring amino acid, or is absent, provided that if X3 is N, then X4 must be an amino acid other than G or N (SEQ ID NO:2);
b) a second peptide linker; and
c) a human IgG Fc region;
wherein the C-terminal residue of the insulin receptor agonist is directly fused to the N-terminal residue of the second peptide linker, and the C-terminal residue of the second peptide linker is directly fused to the N-terminal residue of the human IgG Fc region.
US Pat. No. 10,711,047

CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME

ONCOTHERAPY SCIENCE, INC....

1. A method of inducing an immune response against a cancer expressing CDCA1 in a subject whose HLA is HLA-A*2402, said method comprising the step of administering an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 23 to said subject.
US Pat. No. 10,711,303

CETP INHIBITORS FOR THERAPEUTIC USE

Hoffman-La Roche Inc., L...

1. A method for treating a cardiovascular disorder, comprising administering an effective amount of torcetrapib, anacetrapib, evacetrapib, BAY 60-5521, DEZ-001, ATH-03, DRL-17822 or DLBS-1449 to a subject in need thereof and known to carry one or more of the following improved response genotypes: rs1967309/AA, rs1967309/AG, rs12595857/GG, rs12595857/AG, rs111590482/AG, rs111590482/GG, rs11647828/AG, rs12935810/GG, rs17136707/GG, rs17136707/AG, rs2239310/GG, rs2239310/AG, rs2283497/AA, rs2283497/CA, rs2531967/AA, rs2531967/GA, rs3730119/AA, rs3730119/GA, rs4786454/AA, rs4786454/GA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8049452/GA, rs8061182/AA, rs8061182/AG, rs11647828/GG, and rs13337675/AG.
US Pat. No. 10,709,767

AGENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF PERIPHERAL NEUROPATHIC PAIN CAUSED BY ANTICANCER AGENT

KINKI UNIVERSITY, Osaka ...

1. A method for treating chemotherapy-induced peripheral neuropathic pain caused by paclitaxel, docetaxel, oxaliplatin, or nedaplatin in a cancer patient, which comprises:administering paclitaxel, docetaxel, oxaliplatin or nedaplatin to the patient; and
administering thrombomodulin to the patient between 12 hours before and 6 hours after the administration of the paclitaxel, docetaxel, oxaliplatin or nedaplatin to the patient.
US Pat. No. 10,711,048

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that selectively recognize cells that present a peptide consisting of the amino acid sequence of QYQNVLTLW (SEQ ID NO: 31), wherein the cancer is selected from lung cancer, brain cancer (GBM), gastric cancer (GC), hepatocellular carcinoma (HCC), melanoma (MEL), non-Hodgkin lymphoma (NHL), prostate cancer and benign prostate hyperplasia (PRCA), renal cell carcinoma (RCC), and uterine cancer (UEC).
US Pat. No. 10,711,304

METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING

UNIVERSITY OF WASHINGTON ...

1. A method for testing a mutagenic potential of a substance, comprising:(a) preparing a sequencing library from a sample comprising a plurality of double-stranded DNA fragments from a biological source exposed to the substance, wherein preparing the sequence library comprises ligating adapter molecules to the plurality of double-stranded DNA fragments to generate a plurality of adapter-DNA molecules;
(b) sequencing first and second strands of the adapter-DNA molecules to provide a first strand sequence read and a second strand sequence read for each of a plurality of adapter-DNA molecules;
(c) for each adapter-DNA molecule among at least a portion of the adapter-DNA molecules, comparing the first strand sequence read and the second strand sequence read to identify one or more correspondences between the first and second strand sequence reads; and
(d) determining a mutagenic potential of the substance by analyzing the one or more correspondences between the first and second strand sequence reads for each of the adapter-DNA molecules among at least the portion of the adapter-DNA molecules and comparing said one or more correspondences to a reference sequence to determine at least one of a mutation spectrum, a mutation pattern, a mutation frequency, a mutation type, a copy number variation, a DNA damage signature and a genomic distribution of mutations in the sample.
US Pat. No. 10,709,768

CHONDROCYTE EXTRACELLULAR MATRIX-DERIVED PEPTIDE

EYEBIO KOREA, Gimhae-si,...

1. A peptide consisting of an amino acid sequence represented by SEQ ID NO: 1.
US Pat. No. 10,711,049

METHOD FOR PRODUCING TLR5 AGONIST PROTEIN

Korea Institute of Indust...

1. A method of producing a Toll-like receptor-5 (TLR5) agonist protein, comprising the steps of:(a) producing a vector that comprises (i) a fusion nucleic acid that encodes the TLR5 agonist protein that comprises the amino acid sequence of SEQ ID NO: 2 and the amino acid sequence of SEQ ID NO: 4; (ii) a nucleic acid that encodes ubiquitin, and (iii) a nucleic acid that encodes a tag for purification;
(b) producing a fusion protein by transforming a host with the vector in step (a) and then expressing the fusion nucleic acid;
(c) recovering the fusion protein by binding the fusion protein of step (b) to a column that the tag for purification binds; and
(d) recovering the TLR5 agonist protein by treating the recovered fusion protein of step (c) with a ubiquitin cleavage enzyme to cleave the site to which the ubiquitin binds,
wherein the ubiquitin cleavage enzyme is ubiquitin-specific protease (USP) or ubiquitin C-terminal hydrolase (UCH),
wherein the fusion nucleic acid has a nucleotide sequence as set forth in SEQ ID NO: 7.
US Pat. No. 10,709,769

USE OF ENDOSTATIN PEPTIDES FOR THE TREATMENT OF FIBROSIS

1. A composition comprising:a polypeptide, wherein the polypeptide consists of amino acids 133-180 of SEQ ID NO: 2 with at most 5 amino acid substitutions, wherein the polypeptide has anti-fibrotic activity, wherein the polypeptide is fused to a heterologous peptide, and
a pharmaceutically acceptable carrier.
US Pat. No. 10,711,306

METHOD AND KIT FOR MULTIPLEX DNA TYPING OF HLA GENE

GENODIVE PHARMA INC., Ka...

1. A method for DNA typing of HLA in which phase ambiguity due to unclear cis/trans positional relationships is eliminated, or a null allele or a novel allele is detected, comprising the following steps:(1) a step of preparing sets of primers which respectively hybridize specifically to an upstream region and a downstream region of at least four genes comprising HLA-A, HLA-B, HLA-C, and HLA-DRB1 genes in a human genome sequence, and are capable of amplifying under the same PCR conditions wherein:
the HLA-A gene is amplified by a primer set comprising an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 1 or 2 and an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 3;
the HLA-B gene is amplified by a primer set comprising an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 4 and an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 5;
the HLA-C gene is amplified by a primer set comprising an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 6 or 7 and an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 8; and
the HLA-DRB1 gene is amplified by a primer set comprising an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 9 and an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 10, and/or a primer set comprising an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 11 and an oligonucleotide comprising the nucleotide sequence as shown in SEQ ID NO: 12;
(2) a step of simultaneously amplifying said at least four genes in a test sample (DNA) using the sets of primers in a single container under the same PCR conditions;
(3) a step of sequencing the resulting PCR amplified products; and
(4) a step of typing of said at least four genes at an 8-digit level by comparing with nucleotide sequences of known HLA alleles, wherein if said at least four genes are discriminated at an 8-digit level, typing without phase ambiguity is performed, or a null allele or novel allele, if present, is detected.
US Pat. No. 10,709,770

NUTRITIONAL COMPOSITIONS CONTAINING A PREBIOTIC AND LACTOFERRIN AND USES THEREOF

MEAD JOHNSON NUTRITION CO...

10. A nutritional composition for reducing constipation in a pediatric subject, comprising:up to about 7 g/100 kcal of a fat or lipid source, wherein the fat or lipid source comprises milk fat globules derived from an enriched lipid fraction from bovine milk, wherein the enriched lipid fraction comprises from about 0.2 g/100 kcal to about 5.82 g/100 kcal of branched chain fatty acids and from about 50 mg/100 kcal to about 200 mg/100 kcal of phospholipids;
up to about 5 g/100 kcal of a protein source;
between about 15 mg/100 kcal and about 300 mg/100 kcal of lactoferrin from a non-human source;
about 0.015 g/100 kcal to about 1.5 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises polydextrose and galactooligosaccharide;
a source of long chain polyunsaturated fatty acids comprising docosahexaenoic acid, arachidonic acid, and combinations thereof; and
a preservative comprising potassium sorbate, sodium sorbate, potassium benzoate, sodium benzoate, calcium disodium EDTA, or a combination thereof, and
wherein upon administration of the nutritional composition the pediatric subject experiences a reduction in constipation.
US Pat. No. 10,710,026

ZWITTERIONIC FIBER MEMBRANES

Trustees of Tufts College...

1. A polymer fiber, comprising a plurality of statistical copolymers, wherein each statistical copolymer comprises a plurality of zwitterionic repeat units and a plurality of hydrophobic repeat units, whereinthe zwitterionic repeat units constitute 20-75 wt % of the statistical copolymer;
the hydrophobic repeat units are characterized in that a homopolymer formed thereof has a glass transition temperature above room temperature;
each of the zwitterionic repeat units independently comprises sulfobetaine, carboxybetaine, phosphorylcholine, or pyridinium alkyl sulfonate;
each of the hydrophobic repeat units independently is formed of styrene, fluorinated styrene, methyl methacrylate, acrylonitrile, or trifluoroethyl methacrylate; and
the polymer fiber is uniformly made from the statistical copolymer.
US Pat. No. 10,711,051

MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS

ZYMEWORKS INC., Vancouve...

1. A heteromultimer comprising:(i) a first monomeric protein that comprises a first transporter polypeptide comprising a first segment of albumin, and at least one cargo polypeptide, and
(ii) a second monomeric protein that comprises a second transporter polypeptide comprising a second segment of albumin, and at least one cargo polypeptide;
wherein the first segment of albumin and the second segment of albumin are derived from an albumin by segmentation of the albumin, the first transporter polypeptide is different from the second transporter polypeptide, and the transporter polypeptides self-assemble to form a quasi-native albumin structure.
US Pat. No. 10,711,307

METHOD FOR DETERMINING STATE OF DIFFERENTIATION OF STEM CELLS, AND NOVEL DIFFERENTIATION MARKER USED THEREFOR

FUJIFILM WAKO PURE CHEMIC...

1. A method for preparing differentiated stem cells comprising:(a) subjecting undifferentiated stem cells to differentiation-inducing treatment,
(b) detecting an expression of FOXB2 gene in the stem cells, and
(c) isolating the stem cells in which the expression of FOXB2 gene is detected.
US Pat. No. 10,709,771

METHOD FOR PREVENTING OR TREATING DIABETIC RETINOPATHY

TALENGEN INTERNATIONAL LI...

1. A method for preventing and/or treating retinopathy caused by diabetes mellitus in a subject, comprising administering an effective amount of plasminogen to the subject, wherein the plasminogen is selected from Glu-plasminogen, Lys-plasminogen, mini-plasminogen, micro-plasminogen, ? (delta)-plasminogen or any combination thereof.
US Pat. No. 10,711,052

METHOD FOR PROMOTING WOUND HEALING

UNIVERSITY OF SOUTHERN CA...

1. A method for treating or accelerating healing of a wound in the skin of a subject having epidermolysis bullosa, comprising:intravenously administering to the subject having epidermolysis bullosa and the skin wound an effective amount of a pharmaceutical composition comprising recombinant human collagen type VII protein comprising an alpha chain having a collagenous triple-helical segment.
US Pat. No. 10,711,308

MUTATION SIGNATURES FOR PREDICTING THE SURVIVABILITY OF MYELODYSPLASTIC SYNDROME SUBJECTS

DANA-FARBER CANCER INSTIT...

1. A method of aggressively treating myelodysplastic syndrome (MDS) in a subject, the method comprising:(a) detecting whether one or more protein sequence-disrupting mutations is present in each of genes TP53, ETV6, EZH2, RUNX1 and ASXL1 in a polynucleotide sample obtained from a subject, using a nucleic acid detection assay;
(b) diagnosing the subject as needing aggressive treatment for MDS when one or more mutations is detected in two or more of the TP53, ETV6, EZH2, RUNX1 and ASXL1 genes; and
(c) administering an effective amount of an aggressive drug regimen comprising azacytidine, decitabine, lenalidomide, and/or bone marrow transplantation, to the subject diagnosed in step (b) to aggressively treat MDS.
US Pat. No. 10,709,772

USE OF BOTULINUM NEUROTOXIN IN THE TREATMENT OF SIALORRHEA

1. A method for treating a disease or condition associated with sialorrhea or increased saliva production in a patient, the method comprising administering a therapeutically effective amount of a botulinum neurotoxin by injection into the parotid glands and submandibular glands of the patient, in at least two consecutive treatment cycles, wherein:the disease or condition is further associated with Parkinson's disease, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, Amyotrophic lateral sclerosis (ALS), stroke, traumatic brain injury (TBI), clozapine induced hypersalivation, Rett syndrome, Angelman syndrome, epileptic encephalopathy, brain tumours, total pharyngolaryngectomy, supracricoid laryngectomy, supraglottic laryngectomy, dementia, or intellectual disability;
there is a time interval between at least two consecutive treatment cycles of between 10 and 20 weeks; and
the ratio between the amount of the botulinum neurotoxin administered into each of the parotid glands and each of the submandibular glands is between 1.45 to 1 and 1.7 to 1.
US Pat. No. 10,711,053

INSULIN LIKE PEPTIDES

1. A method for making a chimeric polypeptide comprising two different peptide chains, wherein the two different peptide chains are chain A from one insulin like peptide and chain B from a different insulin like peptide, wherein chain A is selected from the A chain of insulin (INS), INSL3 (RLF), INSL4, INSL5, INSL6 (RIF-1), Relaxin 1 (RLN1), Relaxin 2 (RLN2), insulin-like growth factor 1 (IGF-1), and insulin-like growth factor 2 (IGF-2), and chain B is selected from the B chain of insulin (INS), INSL3 (RLF), INSL4, INSL5, INSL6 (RIF-1), Relaxin 1 (RLN1), Relaxin 2 (RLN2), insulin-like growth factor 1 (IGF-1), and insulin-like growth factor 2 (IGF-2); the method comprising(i) combining a chain A which contains at least two disulfide bonds, with a chain B which contains at least one disulfide bond, in the presence of a reducing agent; or
(ii) combining a chain A which contains at least two disulfide bonds, with a chain B which contains at least two cysteine residues, in the presence of dimethyl sulfoxide (DMSO);
thereby making the chimeric polypeptide.
US Pat. No. 10,711,309

SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA FROM TARGET INDIVIDUALS USING GENETIC DATA FROM GENETICALLY RELATED INDIVIDUALS

Natera, Inc., San Carlos...

1. A method for determining genetic data for DNA from cancer cells, the method comprising:isolating cell-free DNA from a biological sample and amplifying a plurality of target loci from the isolated cell-free DNA to obtain amplification products;
using high throughput DNA sequencing to detect genetic material from the amplification products and produce genetic data for the plurality of target loci on the chromosome or chromosome segment of interest;
creating a set of one or more hypotheses specifying genetic data for DNA from cancer cells; determining the probability of each of the hypotheses given the produced genetic data; and using the probabilities associated with each hypothesis to determine the most likely genetic data for DNA from cancer cells.
US Pat. No. 10,709,773

SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION

Synthetic Biologics, Inc....

1. A method of protecting a human patient's gastrointestinal microbiome, comprising administering an amount of a pharmaceutical composition comprising a beta-lactamase to a patient in need thereof, wherein:the patient is undergoing treatment or has recently undergone treatment with a beta-lactam antibiotic, optionally selected from a penicillin and a cephalosporin;
the patient is undergoing treatment with a proton pump inhibitor, wherein the proton pump inhibitor is esomeprazole;
the beta-lactamase comprises the amino acid sequence of SEQ ID NO: 1 and
the amount of beta-lactamase is 150 mg.
US Pat. No. 10,710,029

METHOD OF PREPARING HYBRID MEMBRANE

NANJING UNIVERSITY, Nanj...

1. A method, comprising:1) mixing a granular material and a dispersant, to yield a dispersion solution;
2) mixing a polymer and an organic solvent, to yield a matrix solution; adding the matrix solution to the dispersion solution to yield a mixed solution;
3) heating the mixed solution obtained in 2) to remove the dispersant, to yield a casting solution; and
4) coating the casting solution on a substrate, followed by removing the organic solvent, to yield a hybrid membrane.
US Pat. No. 10,711,310

TERT PROMOTER MUTATIONS IN GLIOMAS AND A SUBSET OF TUMORS

Duke University, Durham,...

1. A method of identifying a mutation in a human subject and treating a human subject, comprising:subjecting a nucleic acid sample obtained from a tumor of the human selected from the group consisting of: glioma, astrocytoma, oligodendroglioma, and oligoastrocytoma, to a reaction whereby reaction products are formed;
detecting in the reaction products from the human tumor a somatic mutation at nucleotide chr5 1,295,228 in hg19; and
administering to the subject with the somatic mutation a therapy selected from the group consisting of chemotherapy, radiotherapy, biological therapy, or surgery.
US Pat. No. 10,709,774

IMMUNOMODULATORY PHARMACEUTICAL COMPOSITIONS

Enzo Biochem, Inc., New ...

1. A pharmaceutical composition, comprisinga synthetic peptide which is GEPIPVTVDVTNNTEKTVKK (SEQ ID NO: 2); and
rapamycin.
US Pat. No. 10,711,055

TYPE III SECRETION SYSTEM TARGETING MOLECULES

Inhibrx, Inc., La Jolla,...

1. A method for treating an infectious disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated polypeptide comprising a first VHH domain that binds PcrV from Pseudomonas aeruginosa, wherein the first VHH domain comprises the CDRs of SEQ ID NO: 41, as determined by Chothia numbering.
US Pat. No. 10,711,311

GENOMIC REARRANGEMENTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USING THE SAME

The Henry M. Jackson Foun...

1. A method of detecting a genomic rearrangement in a biological sample, the method comprising detecting the genomic rearrangement in the biological sample obtained from a subject, wherein the subject is a human and wherein the biological sample comprises prostate cells or nucleic acid or polypeptides isolated from the prostate cells and wherein the genomic rearrangement occurs in chromosome region 3q13 and is a gene fusion, a gene deletion, or a gene duplication of a ZBTB20 gene and an LSAMP gene and wherein detecting the genomic rearrangement in the biological sample comprises:(a) detecting a gene duplication that results in a fusion between exon 1 of the ZBTB20 gene and exon 4 of the LSAMP gene;
(b) detecting a fusion between exon 1 of the ZBTB20 gene and exon 3* of the LSAMP gene; or
(c) detecting a deletion in chromosome region 3q13, wherein the deletion spans both the ZBTB20 and LSAMP genes or results in a fusion between the ZBTB20 and LSAMP genes.
US Pat. No. 10,709,775

CELLS FOR IMMUNOTHERAPY ENGINEERED FOR TARGETING CD38 ANTIGEN AND FOR CD38 GENE INACTIVATION

Cellectis, Paris (FR)

1. An anti-CD38 specific chimeric antigen receptor (anti-CD38 CAR) comprising an extra cellular ligand binding-domain comprising VH and VL from a monoclonal anti-CD38 antibody, a hinge, a transmembrane domain, and a cytoplasmic domain comprising a CD3 zeta signaling domain and a co-stimulatory domain from 4-1BB,wherein said VH and VL comprise the CDRs sequences of respectively SEQ ID NO.15-17 and SEQ ID NO.11-13; respectively SEQ ID NO.63-65 and SEQ ID NO.59-61; respectively SEQ ID NO.55-57 and SEQ ID NO.51-53; respectively SEQ ID NO.31-33 and SEQ ID NO.27-29; respectively SEQ ID NO.39-41 and SEQ ID NO.35-37; respectively SEQ ID NO.47-49 and SEQ ID NO.43-45; respectively SEQ ID NO.23-25 and SEQ ID NO.19-21.
US Pat. No. 10,711,057

METHODS OF SHIFTING AN ISOELECTRIC PROFILE OF A PROTEIN PRODUCT AND USES THEREOF

Alexion Pharmaceuticals, ...

1. Eculizumab comprising seven protein subpopulations with an isoelectric point between about 5.45 and about 6.55 produced by a method comprising:(a) fed batch culturing mammalian cells comprising a nucleic acid encoding eculizumab in a production bioreactor under conditions sufficient to produce eculizumab for a first period of time comprising a growth phase or a growth phase and a stationary phase of the mammalian cells or that comprises a growth phase of the mammalian cells and terminates at a critical time point; and
(b) incubating eculizumab under conditions sufficient to shift the isoelectric profile of eculizumab toward a more acidic profile for a second period of time comprising incubating eculizumab in a medium having (i) a dissolved oxygen (dO2) concentration of between about 20% to about 45%, (ii) a pH of between about 7.0 and about 7.3, (iii) a temperature of between about 30° C. and about 37.5° C., or (iv) a dO2 concentration of between about 20% to about 45%, a pH of between about 7.0 and about 7.3, and a temperature of between about 30° C. and about 37.5° C.,
wherein the more acidic profile comprises an increase in the quantity of the fourth and fifth most acidic protein subpopulations of the seven protein subpopulations, and a decrease in the quantity of the first and second most basic protein subpopulations of the seven protein subpopulations.
US Pat. No. 10,709,777

SALMONELLA PARATYPHI A WITH AN O-ANTIGEN HAVING AN EXTENDED CARBOHYDRATE CHAIN AND USE THEREOF

Institute of Biotechnolog...

1. A recombinant strain, which is obtained by introducing a cldLT2 gene encoding an enzyme controlling chain length of O-antigen of Salmonella typhimurium into Salmonella paratyphi A which is deficient in cld gene encoding an enzyme controlling chain length of O-antigen;wherein the amino acid sequence of the enzyme controlling chain length of the O-antigen of Salmonella typhimurium has the amino acid sequence as shown in SEQ ID NO: 2.
US Pat. No. 10,711,058

ANTI-TAU ANTIBODIES AND METHODS OF USE

AC Immune SA, Lausanne (...

1. An isolated antibody that binds to human Tau, wherein the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 605; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 606; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 607; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 608; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 609; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 610.
US Pat. No. 10,711,314

METHODS FOR DIAGNOSING IDH-MUTANT CELL PROLIFERATION DISORDERS

Agios Pharmaceuticals, In...

1. A method of diagnosing a subject having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder associated with:(a) the presence, distribution, or level of an IDH1 mutant enzyme that has 2-hydroxyglutarate (2HG) neoactivity and has other than an Arg at residue 100; or
(b) elevated levels of 2HG due to the presence of an IDH1 mutant enzyme that has 2HG neoactivity and has other than an Arg at residue 100,wherein said method comprises analyzing the presence, distribution, or level of 2HG in the subject or a tissue, bodily product, or bodily fluid of said subject by mass spectroscopy analysis and wherein if the subject or the tissue, bodily product, or bodily fluid shows an increase in the presence, distribution or level of 2HG compared to a non-diseased subject, tissue, bodily product or bodily fluid of the same type, then the subject is diagnosed as having the cell proliferation related disorder.
US Pat. No. 10,711,059

METHODS FOR TREATING NEURODEGENERATIVE DISEASES USING ANTI-PD-L1 ANTIBODIES

Kymab Limited, Cambridge...

1. A method of treating or reducing the risk of a neurodegenerative disease in a human, the method comprising administering to said human an anti-PD-L1 antibody or antibody fragment that specifically binds to a human PD-L1 that is expressed by a PD-L1 nucleotide sequence comprising a variation selected from the group consisting of:rs1411262; rs4143815; 8923C; rs150439231; rs138261640; rs142983488; rs76741468; rs822336; rs183400620; rs187252832; rs146143976; rs139023765; rs73641615; rs17718883; rs139709512; rs140045210; rs141978642; rs146495642; rs370800260; rs143235887; rs373692552; rs140304675; rs12551333; rs376993991; rs367921713; rs41280721; rs61752860; rs148141792; rs369350813; rs10481593; rs2282055; rs2297135; rs2297136; rs2297137; rs3780395; rs7023227; rs1411262; rs34028061; rs7041009; rs148170925; rs10114060; rs1536926; and rs7042084;wherein the antibody or antibody fragment that specifically binds to human PD-L1 comprises:(i) a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of:
an Asp corresponding to position 204 of SEQ ID NO: 42 and a Leu corresponding to position 206 of SEQ ID NO: 42; or
(ii) a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of:
an Glu corresponding to position 204 of SEQ ID NO: 42 and a Met corresponding to position 206 of SEQ ID NO: 42; or
(iii) a human gamma-4 heavy chain constant region that comprises an amino acid selected from the group consisting of:
a Leu corresponding to position 189 of SEQ ID NO: 73 and an Arg corresponding to position 289 of SEQ ID NO: 73; andwherein the antibody or antibody fragment comprises the variable domains of an antibody selected from the group consisting of:durvalumab, atezolizumab, STI-A1014, avelumab, and BMS-936559; andwherein said human comprises:(iv) an IGHG1*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid of clause (i), when the antibody or fragment is according to clause (i); or
(v) an IGHG1*03 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid of clause (ii), when the antibody or fragment is according to clause (ii); or
(vi) an IGHG4*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-4 heavy chain constant regions comprising said selected amino acid of clause (iii), when the antibody or fragment is according to clause (iii); andwherein said human comprises:(vii) a PD-L1 nucleotide sequence comprising said selected variation,wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, and Huntington's disease.
US Pat. No. 10,711,315

METHOD FOR PRODUCING RNA

1. A method for producing purified mRNA on a preparative scale comprising the following steps:a) providing a template DNA comprising a nucleic acid sequence encoding a mRNA sequence;
b) in vitro transcription of the template DNA in order to obtain a composition comprising the mRNA;
c) purification of a preparative quantity of the mRNA obtained in step b) by purification steps comprising, at least:
i) oligo dT-based affinity purification; and
ii) RP-HPLC,
thereby producing a preparative quantity of purified mRNA.
US Pat. No. 10,709,779

NUCLEIC ACID VACCINES

ModernaTX, Inc., Cambrid...

1. A method of vaccinating a subject comprising administering to the subject a nucleic acid vaccine comprising one or more messenger ribonucleic acid (mRNA) polynucleotides comprising an open reading frame encoding an antigenic polypeptide that is derived from an infectious agent, wherein the mRNA polynucleotide is not self-replicating RNA, wherein the mRNA polynucleotides are formulated within a cationic lipid nanoparticle having a molar ratio of about 20-60% ionizable cationic lipid: about 5-25% non-cationic lipid: about 25-55% sterol; and about 0.5-15% PEG-modified lipid, wherein the nucleic acid vaccine elicits an immune response having a longer lasting antibody titer than an antibody titer elicited by a reference nucleic acid vaccine comprising the one or more mRNA polynucleotides not formulated within a cationic lipid nanoparticle having a molar ratio of about 20-60% ionizable cationic lipid: about 5-25% non-cationic lipid: about 25-55% sterol; and about 0.5-15% PEG-modified lipid.
US Pat. No. 10,711,060

ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF

NOVARTIS AG, (CH) Immute...

1. An isolated nucleic acid molecule comprising a first nucleotide sequence that encodes a VH and a second nucleotide sequence that encodes a VL of an antibody molecule that binds to human LAG-3, wherein the antibody molecule comprises:(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 4, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 15;
(b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12;
(c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 15; or
(d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12.
US Pat. No. 10,711,316

PRIMERS AND KITS FOR COLONY MULTIPLEX PCR FOR THE DETECTION OF CLASS A, B, C, AND D BETA-LACTAMASE GENES AND METHODS OF USING THEREOF

MYONGJI UNIVERSITY INDUST...

1. A method for treating a patient with bacterial infection, the method comprising:determining a ?-lactamase (bla) gene of a bacterial pathogen in the patient by performing a multiplex polymerase chain reaction (PCR) with primer pairs;
determining a ?-Lactam antibiotics to which the bacterial pathogen is not resistant, in accordance with the determination of the ?-lactamase (bla) gene; and
administering the ?-Lactam antibiotics to the patient,
wherein the primer pairs comprise:
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 1 and 2, a pair of Seq. 3 and 4, a pair of Seq. No. 5 and 6, a pair of Seq. No. 7 and 8, a pair of Seq. No. 9 and 10, a pair of Seq. No. 11 and 12, a pair of Seq. No. 13 and 14, and a pair of Seq. No. 15 and 16;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 17 and 18, a pair of Seq. No. 19 and 20, a pair of Seq. No. 21 and 22, a pair of Seq. No. 23 and 24, and a pair of Seq. No. 25 and 26;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 27 and 28, a pair of Seq. No. 29 and 30, a pair of Seq. No. 31 and 32, a pair of Seq. No. 33 and 34, a pair of Seq. No. 35 and 36, a pair of Seq. No. 37 and 38, a pair of Seq. No. 39 and 40, and a pair of Seq. No. 41 and 42;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 43 and 44, a pair of Seq. No. 45 and 46, a pair of Seq. No. 47 and 48, a pair of Seq. No. 49 and 50, a pair of Seq. No. 51 and 52, a pair of Seq. No. 53 and 54, No. 55 and 56, and a pair of Seq. 57 and 58;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 59 and 60, a pair of Seq. No. 61 and 62, a pair of Seq. No. 63 and 64, a pair of Seq. No. 65 and 66, and a pair of Seq. No. 67 and 68;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 69 and 70, a pair of Seq. No. 71 and 72, a pair of Seq. No. 73 and 74, a pair of Seq. No. 75 and 76, a pair of Seq. No. 77 and 78;
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 79 and 80, a pair of Seq. No. 81 and 82, a pair of Seq. No. 83 and 84, a pair of Seq. No. 85 and 86, a pair of Seq. No. 87 and 88, a pair of Seq. No. 89 and 90, a pair of Seq. No. 91 and 92, and a pair of Seq. No. 93 and 94; and
at least two primer pairs selected from the primer pair group consisting of a pair of Seq. No. 95 and 96, a pair of Seq. No. 97 and 98, a pair of Seq. No. 99 and 100, a pair of Seq. No. 101 and 102, a pair of Seq. No. 103 and 104, a pair of Seq. No. 105 and 106, and a pair of Seq. No. 107 and 108.
US Pat. No. 10,709,780

INTEGRIN ACTIVATOR VACCINE COMPOSITIONS

7 Hills Pharma LLC, Hous...

1. A composition comprising:(A) an antigen, and
(B) an adjuvanting amount of at least one integrin activating compound that increases an immune response to the antigen,
wherein the at least one integrin activating compound comprises one or more compounds of the general Formula (I):
R1-M1-N(R2)-M2-M3-M4-M5-M6-R3  (I)
wherein a first class of the compounds of Formula (I) is defined by:
R1 is selected from the group consisting of aryl and aralkyl,
R2 is alkyl, aryl, or aralkyl,
M1 is CH2,
M2 is CO,
M3 is O, S, or NR6,
R6 when present is hydrogen or lower alkyl,
M4 is absent or CH2,
M5 is (CR11R12),
R11 is hydrogen,
R12 is selected from the group consisting of hydrogen, NR21CONR22R23, NR21COR24, NR21SO2R24, NR21COOR24, OCOR24, OR24, O(CH2CH2O)sR24, COOR24, alkyl, and hydroxyalkyl,
s is an integer of 1 to 6,
R21 and R22 when present are independently selected from the group consisting of hydrogen or lower alkyl,
R23 when present is selected from the group consisting of hydroxyalkyl, alkoxyalkyl, alkyl, aryl, aralkyl and alkoxycarbonylalkyl,
 provided that when M3 is NR6 and M4 is absent, then R23 is not 1-(1,3-benzodioxol-5-yl)-3-ethoxy-3-oxopropyl,
R24 when present is selected from the group consisting of alkyl, aryl, aralkyl, heterocyclyl, cycloalkyl, cycloalkylalkyl, and heterocyclylalkyl, and mixtures thereof,
M6 is (CH2)q, where
q is an integer from 0 to 6,
R3 is selected from the group consisting of hydrogen, CONR13R14, NR15COOR16, NR15COR16, NR15CONR13R14, NR15SO2R16, OCOR16, COOR16, OR16, SR16, heterocyclyl, hydroxyl, hydroxyalkyl, guanadino, alkyl and aryl,
R13 and R15 when present are independently hydrogen or lower alkyl,
R14 and R16 when present are independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, and heterocyclylalkyl,
R1, R2, R3, R12, R14, R16, R23 and R24 when present may independently be either unsubstituted or substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, —NHCO(alkyl), —NHCO(aryl), —NHCO(aralkyl), —NHCO(haloalkyl), —NHSO2(alkyl), —NHSO2(aryl), —NHSO2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, —OCO(alkylamino), —OCO(dialkylamino), and mixtures thereof;orwherein a second class of the compounds of Formula (I) is defined by:
R1 is aryl or aralkyl,
R2 is alkyl or aralkyl,
M1 is CH2,
M2 is CO,
M3 is absent or is O or CH2,
M4 is absent or is CH2,
M5 is absent or is O or (CR11R12),
R11 is hydrogen,
R12 is selected from the group consisting of hydrogen, NR21CONR22R23,
NR21COR24, NR21SO2R24 and NR21COOR24,
R21 and R22 each of which, when present is independently selected from the group of hydrogen and lower alkyl,
R23 and R24, each of which, when present is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl,
M6 is selected from the group consisting of (CH2)q, (CH2)q—CH?CH—(CH2)r, (CH2)q-arylene-(CH2)r and (CH2CH2O)q, where
q and r are independently integers from 0 to 6,
R3 is CONR13R14,
R13 and R14, each of which, when present is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl, and
R1, R2, R13, R14, R23 and R24, when present, independently either are unsubstituted or are substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, —NHCO(alkyl), —NHCO(aryl), —NHCO(aralkyl), —NHCO(haloalkyl), —NHSO2(alkyl), —NHSO2(aryl), —NHSO2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, —OCO(alkylamino), —OCO(dialkylamino), and mixtures thereof;orwherein a third class of the compounds of Formula (I) is defined by:
R1 is aryl or aralkyl,
R2 is alkyl or aralkyl,
M1 is CH2,
M2 is SO2, or CO,
M3 is absent or is CH2,
M4 is absent or is CH2,
M5 is absent or is (CR11R12),
R11, when present, is hydrogen,
R12, when present, is selected from the group consisting of hydrogen, alkyl,
NR21CONR22R23, NR21COR24, NR21SO2R24 and NR21COOR24,
R21 and R22, each of which when present, is independently selected from the group of hydrogen, lower alkyl, and aralkyl,
R23 and R24, each of which, when present is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl,
M6 is (CH2)q, or NR34(CH2)q,
q is an integer from 0 to 6,
R34, when present, is selected form the group consisting of alkyl, aralkyl, COR35, and SO2R35,
R35 when present, is selected form the group consisting of alkyl, aryl, and aralkyl, and
R3 is selected from the group consisting of CONR13R14, SO2NR13R14, NR15COOR16, NR15COR16, NR15CONR13R14, and NR15SO2R16,
R13 and R14, each of which, when present, is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl,
R15 and R16, each of which when present, is independently selected from the group of hydrogen, lower alkyl, and aralkyl,
R1, R2, R13, R14, R15, R16, R23, R24, R34 and R35, when present, either are unsubstituted or are substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, —NHCO(alkyl), —NHCO(aryl), —NHCO(aralkyl), —NHCO(haloalkyl), —NHSO2(alkyl), —NHSO2(aryl), —NHSO2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, —OCO(alkylamino), and —OCO(dialkylamino), with the proviso that when M2 is CO, then M6 is NR34(CH2)q,
wherein q is not 0;orwherein a four class of the compounds of Formula (I) is defined by:
R1 is alkyl, aryl or aralkyl,
R2 is selected from the group consisting of aralkyl and alkyl,
provided that when R1 is alkyl, R2 is aralkyl,
M1 is CO or SO2,
provided that when M1 is SO2 and R1 is phenyl, 4-methylphenyl or 2,4,6-trimethylphenyl, R2 is not alkyl, 2-phenethyl, benzyl, or 2-methoxy-2-oxoethyl, and when M1 is CO and R1 is 2-furyl, 4-pyridyl, or 3,5-dinitrophenyl, R2 is not alkyl, benzyl or 2-(1H-indol-2-yl)ethyl,
M2 is absent or CH2,
M3 and M4 are absent,
M5 is (CR11R12),
R11 is hydrogen,
R12 is selected from the group consisting of hydrogen, NR21CONR22R23, NR21COR24, NR21SO2R24, NR21COOR24, CONR22R23, COOR24, O(CH2CH2O)sR24, hydroxyalkyl, and alkoxyalkyl,
R21, and R22, when present, are independently selected from the group consisting of hydrogen and C1-C6 alkyl, and
R23 and R24, each of which, when present, is independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl, and
s is an integer of 1 to 6,
M6 is (CH2)q,
q is an integer of 0 to 6,
R3 is selected from the group consisting of NR15COOR16, NR15COR16, NR15CONR13R14, and NR15SO2R16, and
R13 when present, is independently selected from the group consisting of hydrogen and C1-C6 alkyl, and
R14, R15, and R16 each of which, when present, are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl and aralkyl, and
R1, R2, R3, R12, R14, R15, R16, R23, and R24, when present, independently either are unsubstituted or are substituted with one or more substituents selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heterocyclylaryl, hydroxy, alkoxy, azido, haloalkoxy, hydroxyalkyl, aryloxy, hydroxyaryl, alkoxyaryl, halo, haloalkyl, haloaryl, amino, alkylamino, dialkylamino, arylamino, diarylamino, —NHCO(alkyl), —NHCO(aryl), —NHCO(aralkyl), —NHCO(haloalkyl), —NHSO2(alkyl), —NHSO2(aryl), —NHSO2(aralkyl), alkoxycarbonyl, alkoxycarbonylalkyl, —OCO(alkylamino) and —OCO(dialkylamino),orpharmaceutically acceptable salts thereof.
US Pat. No. 10,711,061

ANTIBODIES AGAINST CANINE PD-1

Intervet Inc., Madison, ...

1. An isolated mammalian antibody or an antigen binding fragment thereof, that binds canine Programmed Death Receptor 1 (canine PD-1) with specificity, said antibody comprising a set of six complementary determining regions (CDRs) that comprises three light chain CDRs: CDR light 1 (CDRL1), CDR light 2 (CDRL2), and CDR light 3 (CDRL3); and three heavy chain CDRs: CDR heavy 1 (CDRH1), CDR heavy 2 (CDRH2) and CDR heavy 3 (CDRH3);(a) wherein CDRL1 comprises the amino acid sequence of SEQ ID NO: 13;
(b) wherein CDRL2 comprises the amino acid sequence of SEQ ID NO: 19;
(c) wherein CDRL3 comprises the amino acid sequence of SEQ ID NO: 25;
(d) wherein CDRH1 comprises the amino acid sequence of SEQ ID NO: 27;
(e) wherein CDRH2 comprises the amino acid sequence of SEQ ID NO: 31; and
(f) wherein CDRH3 comprises the amino acid sequence of SEQ ID NO: 36.
US Pat. No. 10,711,317

DETECTION OF NUCLEIC ACIDS FROM MULTIPLE TYPES OF HUMAN PAPILLOMAVIRUS

GEN-PROBE INCORPORATED, ...

1. A detection reaction mixture comprising at least two detection probe oligomers,wherein a first detection probe oligomer comprises (a) a target-specific sequence selected from the group consisting of SEQ ID NO:11, a complement thereof, and an RNA equivalent thereof, and (b) a detectable label that is joined directly or indirectly to the nucleic acid sequence of (a); and
wherein a second detection probe oligomer comprises (a?) a target-specific sequence selected from the group consisting of SEQ ID NO:12, a complement thereof, and an RNA equivalent thereof, and (b?) a detectable label that is joined directly or indirectly to the nucleic acid sequence of (a?).
US Pat. No. 10,712,341

BIOSENSOR

Duke University, Durham,...

1. A method of assaying for glutamate in a sample, comprising contacting a biosensor with said sample under conditions such that said biosensor is able to bind to glutamate present in said sample, wherein said biosensor comprises Escherichia coil E. coli) glutamate/aspartate binding protein (EBP) comprising a reporter group attached at amino acid position 126 of said E. coil EBP, wherein said E. coli EBP comprises the amino acid sequence set forth in SEQ ID NO: 3, and wherein binding of glutamate in a glutamate-binding pocket of said biosensor causes a change in signaling by said reporter group.
US Pat. No. 10,711,062

ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF

ALECTOR LLC, South San F...

1. An antibody that binds to a CD33 protein, wherein the antibody comprises a heavy chain variable region comprising an HVR-H1, HVR-H2, and HVR-H3 and a light chain variable region comprising an HVR-L1, HVR-L2, and HVR-L3, whereinthe HVR-H1 comprises the amino acid sequence of SEQ ID NO: 105, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 115, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 122, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 135, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 146;
the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 105, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 118, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 122, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 135, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 146;
the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 105, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 119, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 122, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 135, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 146; or
the HVR-H1 comprises the amino acid sequence of SEQ ID NO: 105, the HVR-H2 comprises the amino acid sequence of SEQ ID NO: 120, the HVR-H3 comprises the amino acid sequence of SEQ ID NO: 122, the HVR-L1 comprises the amino acid sequence of SEQ ID NO: 127, the HVR-L2 comprises the amino acid sequence of SEQ ID NO: 135, and the HVR-L3 comprises the amino acid sequence of SEQ ID NO: 146.
US Pat. No. 10,711,318

MICROBIAL STRAIN FOR ELECTROSYNTHESIS AND ELECTROFERMENTATION

UNIVERSITY OF MASSACHUSET...

1. A genetically engineered Geobacter sulfurreducens strain, wherein the strain comprises a genetically engineered modification resulting from the insertion of a genetic element encoding ATP-citrate lyase (EC 2.3.3.8), wherein the strain is capable of effectively growing on a cathode under anaerobic conditions with electrons derived solely from the cathode as electron donor source.
US Pat. No. 10,712,342

DIAGNOSTIC TO DISTINGUISH BACTERIAL INFECTIONS

Arizona Board of Regents ...

1. An array comprising at least two peptides that are capable of differentially binding to one or more antibodies produced in response to a bacterial infection or to one or more antibodies produced in response to a viral infection, wherein said array comprises SEQ ID NO.1 and SEQ ID NO.2.
US Pat. No. 10,709,782

STABLE ANTIBODY CONTAINING COMPOSITIONS

1. A stable, liquid composition comprising an anti-NKG2A monoclonal antibody, arginine, a salt and a buffer, wherein the total concentration of said salt and buffer is lower than 100 mM, wherein the composition comprises:(a) 100 mg/ml of the anti-NKG2A antibody;
(b) 25 mM sodium chloride;
(c) 33 mM histidine buffer;
(d) 25 mM arginine; and
(e) 150 mM sucrose;
buffered to a pH between 5 and 7.
US Pat. No. 10,710,038

WATERLESS DECARBOXYLATION

Ardent LLC, Roslindale, ...

1. A waterless decarboxylation device, comprising:a) a sealed container;
b) a heating element which surrounds the sealed container and is configured to heat the sealed container to over 100° C. for over 30 minutes;
c) a foam layer surrounding the sealed container and the heating element;
e) at least one sensor configured to detect the temperature of the heating element;
f) a lid that encloses the container and fluidly seals it from the environment outside of the container; and
g) a circuit board comprising a controller configured to control power to the heating element in response to signals sent from the at least one sensor indicating whether the heating element has exceeded the temperature 100° C., wherein the controller is configured to control power to the heating element to maintain a temperature of the sealed container at 105° C. for 30 to 90 minutes, and wherein the controller is configured to control power to the heating element to so that the temperature detected at the heating element is not above 130° C.
US Pat. No. 10,711,063

NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES

INNATE PHARMA, Marseille...

1. A method of treating a cancer in a human patient, the method comprising administering to the patient an effective amount of each of: (a) an antibody that neutralizes human NKG2A, and (b) an antibody that neutralizes human PD-L1, wherein the antibody that neutralizes human NKG2A comprises the CDR1, CDR2 and CDR3 domains of a heavy chain having the sequence set forth in any one of SEQ ID NOS: 4-8, and the CDR1, CDR2 and CDR3 domains of a light chain having the sequence set forth in SEQ ID NO: 9 and the antibody that neutralizes human PD-L1 is selected from nivolumab, lambrolizumab, pembrolizumab, atezolizumab, or pidlizumab.
US Pat. No. 10,711,319

METHOD FOR TREATING CELLULOSIC MATERIAL

SilvaNova, LLC, Plymouth...

1. A method comprising(i) contacting a cellulose-comprising input material with an aqueous hydrolyzing solution comprising at least 35% wt. of at least one mineral acid to form a hydrolyzate comprising a mixture of water-soluble carbohydrates and optionally a solid fraction;
(ii) contacting said hydrolyzate with an extractant comprising a first solvent S1, to form (a) a solid first residue comprising precipitated carbohydrates and (b) an acid-comprising extract;
(iii) separating said acid-comprising extract from said solid first residue;
(iv) modifying said acid-comprising extract to form (a) a liquid second residue comprising dissolved carbohydrates and (b) an acid-comprising modified extract, wherein said modifying said acid-comprising extract comprises combining said extract with a second solvent S2;
(v) fractionating said modified extract into an S1-enriched fraction and an acid-enriched fraction;
(vi) reusing said S1-enriched fraction to form said extractant; and
(vii) reusing said acid-enriched fraction to form said aqueous hydrolyzing solution; wherein
(a) at least 10% wt. of the cellulose is hydrolyzed and said mixture of water-soluble carbohydrates comprises monosaccharides, disaccharides and/or oligosaccharides;
(b) S1 forms a single phase when mixed with an identical weight of 70% sulfuric acid aqueous solution at 25° C.;
(c) S1 is at least 65% wt. of said extractant; and
(d) said acid-comprising extract comprises at least 60% wt. of the acid and at least 5% wt. of the carbohydrates in said hydrolyzate.
US Pat. No. 10,712,343

MOLECULAR ANALYSIS OF TUMOR SAMPLES

The General Hospital Corp...

1. A method for treating an intra-abdominal tumor in a subject, the method comprising:obtaining a sample from the subject, wherein the sample is not from breast or lung tissue;
detecting levels of biomarkers consisting of MUC-1, HER2, EGFR, and EpCAM in the sample by contacting the sample with antibodies or antigen-binding fragments thereof that bind to MUC-1, HER2, EGFR, and EpCAM and are labeled with superparamagnetic cross-linked iron oxide (CLIO) nanoparticles having a hydrodynamic diameter of 28.8 nm;
comparing the levels of MUC-1, HER2, EGFR, and EpCAM in the sample to reference levels; and
administering a treatment for cancer to a subject who has levels of MUC-1, HER2, EGFR, and EpCAM above the reference levels.
US Pat. No. 10,711,064

LYM-1 AND LYM-2 TARGETED CAR CELL IMMUNOTHERAPY

University of Southern Ca...

1. A chimeric antigen receptor (CAR) comprising: (a) an antigen binding domain of an anti-HLA-DR antibody; (b) a CD8 ? hinge domain; (c) a CD8 ? transmembrane domain; (d) a CD28 costimulatory signaling region and/or a 4-1BB costimulatory signaling region; and (e) a CD3 zeta signaling domain, wherein the antigen binding domain of an anti-HLA-DR antibody comprises:(i) a heavy chain variable region comprising SEQ ID NO: 8 and a light chain variable region comprising SEQ ID NO: 18; or
(ii) a heavy chain variable region comprising SEQ ID NO: 10 and a light chain variable region comprising SEQ ID NO: 20.
US Pat. No. 10,711,320

REDUCTION AT ELEVATED TEMPERATURE OF COATED STEELS CONTAINING METASTABLE AUSTENITE

AK Steel Properties, Inc....

1. A method of coating a metastable steel comprising the steps of:a. Selecting a metastable steel having an instability factor (IF) greater than or equal to 2.9, wherein IF is calculated by the following equation:
IF=37.193?51.248(% C)?0.4677(% Cr)?1.0174(% Mn)?34.396(% N)?2.5884(% Ni)
b. Prior to coating said metastable steel, annealing said metastable steel;
c. Coating said metastable steel with a metallic coating;
d. After coating said metastable steel, warming said metastable steel to a warming temperature greater than 70° F.; and
e. Rolling said coated and warmed metastable steel.
US Pat. No. 10,714,139

MAGNETIC RECORDING MEDIUM HAVING CHARACTERIZED MAGNETIC LAYER

FUJIFILM Corporation, To...

1. A magnetic recording medium comprising:a non-magnetic support; and
a magnetic layer which is provided on the support and contains ferromagnetic powder and a binder,
wherein the ferromagnetic powder is ferromagnetic hexagonal ferrite powder,
the magnetic layer contains an abrasive,
an intensity ratio (Int (110)/Int (114)) of a peak intensity Int (110) of a diffraction peak of (110) plane of a crystal structure of the hexagonal ferrite, determined by performing X-ray diffraction analysis on the magnetic layer by using an In-Plane method, to a peak intensity Int (114) of a diffraction peak of (114) plane of the crystal structure is equal to or higher than 0.5 and equal to or lower than 4.0,
a squareness ratio of the magnetic recording medium in a vertical direction is equal to or higher than 0.65 and equal to or lower than 1.00, and
a contact angle with 1-bromonaphthalene measured within a surface of the magnetic layer is in a range of 50.0° to 55.00.
US Pat. No. 10,709,784

METAL CHELATING COMPOSITIONS AND METHODS FOR CONTROLLING THE GROWTH OR ACTIVITIES OF A LIVING CELL OR ORGANISM

CHELATION PARTNERS INCORP...

1. A chelating composition soluble in an aqueous medium for chelating iron, said chelating composition comprising:a carrier material; and
one or more suitable metal binding chemical groups having iron chelating activity affixed to or incorporated into the structure of the carrier material;
wherein the one or more suitable metal binding chemical groups is one or more of carboxyl, hydroxyl, phenol ate, catechol ate, hydroxamate or hydroxypyridinone types;
wherein the carrier material comprises vinylpyrrolidone, styrene or acrylamide;
wherein the chelating composition is formed by a first monomer group comprising a metal binding monomer representing the metal binding chemical group copolymerized with a suitable second monomer group representing the carrier material such that the resulting co-polymer remains soluble in aqueous solution and has iron chelating activity;
wherein the chelating composition has a minimum molecular weight sufficiently large so as not to be normally taken up into the intra-cellular aspects internal to a cell membrane of a living cell and is able to bind iron; and
wherein the chelating composition remains substantially soluble in the aqueous medium with its bound iron in the external cellular environment of the living cell thereby preventing uptake of the bound iron into the intra-cellular aspects internal to the cell membrane of the living cell.
US Pat. No. 10,711,065

ANTI-FLT-1 ANTIBODIES IN TREATING BRONCHOPULMONARY DYSPLASIA

1. A method of treating bronchopulmonary dysplasia (BPD) in an infant comprising administering to an infant in need of treatment an effective amount of an anti-Flt-1 antibody or antigen fragment thereof, wherein the anti-Flt-1 antibody or antigen fragment thereof comprises:a VL CDR1 defined by the amino acid sequence of SEQ ID NO: 21,
a VL CDR2 defined by the amino acid sequence of SEQ ID NO: 24,
a VL CDR3 defined by the amino acid sequence of SEQ ID NO: 32,
a HL CDR1 defined by the amino acid sequence of SEQ ID NO: 3,
a HL CDR2 defined by the amino acid sequence of SEQ ID NO: 12, and
a HL CDR3 defined by the amino acid sequence of SEQ ID NO: 17.
US Pat. No. 10,712,345

METHODS AND COMPOSITIONS FOR SINGLE CHAIN VARIABLE REGION ENOX2 ANTIBODIES FOR CANCER DETECTION AND DIAGNOSIS

Mor-NuCo Enterprises, Inc...

1. A cell that expresses an antibody that is a single chain variable region ENOX2-specific antibody fusion protein encoded by a DNA sequence of SEQ ID NOS:1 and 2 separated by a linker, wherein the antibody is fused with an alkaline phosphatase or other protein for single-step detection or imaging.
US Pat. No. 10,711,066

ANTI-CANINE PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA ANTIBODY

Elanco US Inc., Greenfie...

1. A monoclonal antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2, and HCDR3, wherein the amino acid sequence of LCDR1 is given by SEQ ID NO:16, the amino acid sequence of LCDR2 is given by SEQ ID NO: 18, the amino acid sequence of LCDR3 is given by SEQ ID NO: 20, the amino acid sequence of HCDR1 is given by SEQ ID NO: 6, the amino acid sequence of HCDR2 is given by SEQ ID NO: 8, and the amino acid sequence of HCDR3 is given by SEQ ID NO: 10; and wherein the monoclonal antibody binds canine platelet derived growth factor receptor alpha (cPDGFRA).
US Pat. No. 10,711,322

HOT-PRESSED STEEL SHEET MEMBER, METHOD OF MANUFACTURING THE SAME, AND STEEL SHEET FOR HOT PRESSING

NIPPON STEEL CORPORATION,...

1. A steel sheet for hot pressing, comprising:a chemical composition represented by, in mass %:
C: 0.10% to 0.34%;
Si: 0.5% to 2.0%;
Mn: 1.0% to 3.0%;
sol. Al: 0.001% to 1.0% or less;
P: 0.05% or less;
S: 0.01% or less;
N: 0.01% or less;
Ti: 0% to 0.20%;
Nb: 0% to 0.20%;
V: 0% to 0.20%;
Cr: 0% to 1.0%;
Mo: 0% to 1.0%;
Cu: 0% to 1.0%;
Ni: 0% to 1.0%;
Ca: 0% to 0.01%;
Mg: 0% to 0.01%;
REM: 0% to 0.01%;
Zr: 0% to 0.01%;
B: 0% to 0.01%;
Bi: 0% to 0.01%; and
balance: Fe and impurities; and
a steel structure comprising ferrite and cementite, represented, in area %:
a total area ratio of bainite and martensite: 0% to 10%; and
an area ratio of cementite: 1% or more, and
wherein a concentration of Mn in the cementite is 5 mass % or more.
US Pat. No. 10,709,786

CLEAR AQUEOUS SOLUTION

SENJU PHARMACEUTICAL CO.,...

1. An aqueous liquid preparation comprising: (1) (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof, and (2) one benzalkonium chloride or a mixture of benzalkonium chlorides, wherein benzalkonium chloride is represented by the formula:[C6H5CH2N(CH3)2R]Cl
wherein R is an alkyl group having 8-18 carbon atoms, wherein the transmittance of the aqueous liquid preparation at wavelength 600 nm is not less than 98%, and
wherein the one benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 8 carbon atoms,
wherein the one benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 10 carbon atoms,
wherein the one benzalkonium chloride has a concentration of less than 0.003 w/v % or higher than 0.01 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 12 carbon atoms,
wherein the one benzalkonium chloride has a concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 14 carbon atoms,
wherein the one benzalkonium chloride has a concentration other than 0.001 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 16 carbon atoms,
wherein the mixture of the benzalkonium chlorides has a total concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when the mixture comprises (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms, and (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms, or
wherein the mixture of the benzalkonium chlorides has a total concentration of 0.003 w/v % relative to the total amount of the aqueous liquid preparation when the mixture comprises (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms, (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms, and (iii) a third benzalkonium chloride wherein R is an alkyl group having 16 carbon atoms.
US Pat. No. 10,711,067

TREATMENT OF POST-PRANDIAL HYPERINSULINEMIA AND HYPOGLYCEMIA AFTER BARIATRIC SURGERY

XOMA (US) LLC, Emeryvill...

1. A method of treating post-prandial hypoglycemia following bariatric surgery, comprising administering to a subject in need thereof an antibody that is a negative modulator of insulin binding to the insulin receptor and/or insulin action at the insulin receptor in an amount effective to ameliorate post-prandial hypoglycemia, wherein the antibody comprises three heavy chain CDRs set out in SEQ ID NO: 11-13 and three light chain CDRs set out in SEQ ID NO: 26-28.
US Pat. No. 10,711,323

STEEL SHEET, AND PRODUCTION METHOD THEREFOR

JFE Steel Corporation, T...

1. A steel sheet having a composition comprising, in mass %,C: 0.05% or more and 0.20% or less,
Si: 0.60% or more and 1.65% or less,
Mn: 1.8% or more and 3.5% or less,
P: 0.05% or less,
S: 0.005% or less,
Al: 0.08% or less, and
N: 0.0060% or less,
the balance being Fe and inevitable impurities,
the steel sheet having a metallographic structure containing, in terms of an area ratio, ferrite of 25% or more and 65% or less, martensite having iron-based carbides precipitated in the grains thereof of 35% or more and 75% or less, and the balance structure other than the ferrite and the martensite having the iron-based carbides precipitated in the grains thereof of 20% or less (including 0%) in total,
average grain diameters of the ferrite and the martensite having the iron-based carbides precipitated in the grains thereof being respectively 5 ?m or lower, and
a total of concentrations of Si and Mn at interface between the ferrite and the martensite having the iron-based carbides precipitated in the grains thereof being, in terms of an atomic concentration, 5% or more, and
the steel sheet having a tensile strength of 900 MPa or higher.
US Pat. No. 10,709,529

KIT OF PARTS CONTAINING DENTAL MILL BLANK COLOURING SOLUTION

3M Innovative Properties ...

1. A kit of parts for producing a coloured dental article, the kit of parts comprising:a dental mill blank comprising a porous zirconia material;
a colouring solution for colouring the porous zirconia material; and
a set of instructions;
the porous zirconia material comprising:
Zr oxide calculated as ZrO2: from 80 to 97 wt.-%,
Al oxide calculated as Al2O3: from 0 to 0.15 wt.-%,
Y oxide calculated as Y2O3: from 1 to 10 wt.-%, and
Bi oxide calculated as Bi2O3: from 0.01 to 0.2 wt.-%,
the porous zirconia material not comprising Fe calculated as Fe2O3 in an amount of more than 0.01 wt.-%, wt.-% with respect to the weight of the porous zirconia material;
the colouring solution comprising:
solvent(s), and
colouring agent(s) comprising metal ions selected from Tb, Er, Pr, Mn, or combinations thereof,
the colouring solution not comprising Fe ions in an amount of more than 0.01 wt.-%, and
the colouring solution not comprising Bi ions in an amount of more than 0.01 wt.-%, wt.-% with respect to the weight of the colouring solution;
wherein the set of instructions direct a user to apply the colouring solution to at least a portion of the dental mill blank to form the coloured dental article, and
wherein the coloured dental article is fluorescent and producible in more than half of the colours according to the Vita™ Tooth Shade Guide.
US Pat. No. 10,709,787

HYDROGELS OF METHACRYLIC HYALURONIC ACID DERIVATIVES FOR ORAL ENZYME THERAPY IN CELIAC DISEASE

NEMYSIS LIMITED, Dublin ...

1. A composition comprising:at least one exogenous enzyme, said enzyme being selected from the group consisting of prolyl endopeptidase (PEP), endoprotease (EP) and combinations thereof, said enzyme in a concentration between 1 mU/mg and 100 U/mg being entrapped in an HA-EDA-MA hydrogel; and
trehalose in a concentration between 0.1 and 10% w/w with respect to the weight of the HA-EDA-MA hydrogel;
wherein the HA-EDA-MA hydrogel is formed by photocrosslinking HA-EDA-MA derivatives;
wherein the HA-EDA-MA derivatives is formed from hyaluronic acid (HA) or a salt thereof, having a molecular weight between 50,000 and 1,500,000 Daltons, and is formed via activation of at least one hydroxyl group of HA with a carbonating agent chosen between carbonic phenylesters and haloformic phenylesters followed by functionalization of the activated hydroxyl group by reaction with ethylenediamine (EDA) and subsequent reaction with methacrylic anhydride (MA); and wherein the composition is in the form of a freeze dried powder.
US Pat. No. 10,711,068

ANTI-CD133 MONOCLONAL ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

THE UNITED STATES OF AMER...

1. An anti-CD133 monoclonal antibody having an antibody binding site comprising CDR-H1 comprising residues 44-50, 44-53, 49-53 or 48-53 of SEQ ID NO:9, CDR-H2 comprising residues 70-74, 68-76, 68-83 or 65-76 of SEQ ID NO:9, CDR-H3 comprising residues 114-116 or 112-115 or SEQ ID NO:9, CDR-L1 comprising residues 46-58 or 52-60 of SEQ ID NO:11, CDR-L2 comprising residues 74-80 or 70-79 of SEQ ID NO:11, and CDR-L3 comprising residues 113-125 or 113-124 of SEQ ID NO:11.
US Pat. No. 10,712,348

KISSPEPTIN-54 DETECTION BY TANDEM MASS SPECTROMETRY

Quest Diagnostics Investm...

1. A method for determining by mass spectrometry the amount in a sample of two or more kisspeptin-54-derived peptides, said method comprising:(a) enriching the sample comprising two or more kisspeptin-54-derived peptides selected from the group consisting of kisspeptin-54, kisspeptin-53, kisspeptin-52, kisspeptin-54(R14P), kisspeptin-53(R14P), and kisspeptin-52(R14P) by high turbulence liquid chromatography (HTLC);
(b) ionizing the enriched sample to produce two or more kisspeptin-54-derived peptide ions detectable by mass spectrometry;
(c) determining the amount of two or more ions by mass spectrometry, wherein the amount of the ions is used to determine the amounts of the corresponding two or more kisspeptin-54-derived peptides in the sample.
US Pat. No. 10,709,530

PHOTOCURABLE COMPOSITION, DENTURE BASE, AND PLATE DENTURE

MITSUI CHEMICALS, INC., ...

1. A photocurable composition that is used for production by stereolithography of a dental prosthesis, a medical device for intraoral use, or a tooth and/or jaw model, the photocurable composition comprising:a (meth)acrylic monomer component and a photopolymerization initiator;
wherein the (meth)acrylic monomer component comprises:
an acrylic monomer (X) that is at least one selected from diacrylic monomers containing, within one molecule, two aromatic rings and two acryloyloxy groups, and that has a weight average molecular weight of from 400 to 580; and
at least one selected from the group consisting of:
a (meth)acrylic monomer (A) that is at least one selected from di(meth)acrylic monomers not containing, within one molecule, an aromatic ring and containing, within one molecule, one or more ether bonds and two (meth)acryloyloxy groups, and that has a weight average molecular weight of from 200 to 400;
a (meth)acrylic monomer (B) that is at least one selected from (meth)acrylic monomers not containing, within one molecule, an aromatic ring and containing, within one molecule, a ring structure other than an aromatic ring and one (meth)acryloyloxy group, and that has a weight average molecular weight of from 130 to 240; and
a (meth)acrylic monomer (C) that is at least one selected from di(meth)acrylic monomers not containing, within one molecule, an aromatic ring or an ether bond and containing, within one molecule, a hydrocarbon skeleton and two (meth)acryloyloxy groups, and that has a weight average molecular weight of from 190 to 280, and
wherein the photopolymerization initiator is at least one selected from alkylphenone compounds or acylphosphine oxide compounds.
US Pat. No. 10,711,069

METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FC?RACTIVATING AND FC?RINHIBITING

MacroGenics, Inc., Rockv...

1. A polypeptide comprising a variant Fc region, wherein said variant Fc region is a variant of a human IgG Fc region, and wherein said variant Fc region comprises the following amino acid modifications relative to a wild-type Fc region:(a) L235I, F243L, R292P, Y300L, and P396L;
(b) L235Q, F243L, R292P, Y300L, and P396L;
(c) L235V, F243L, R292P, Y300L, and P396L; or
(d) L235P, F243L, R292P, Y300L, and P396L;
wherein the positions are numbered according to the EU index as in Kabat.
US Pat. No. 10,712,349

CIRCULATING KIM-1 LEVELS FOR DETECTION OF PATHOLOGIES ASSOCIATED WITH INJURY TO, OR CANCER OF, THE KIDNEY

1. An assay for diagnosing kidney injury or Renal Cell Carcinoma (RCC) in a subject and treating the subject, consisting essentially of:a. contacting a blood sample obtained from a subject identified to have, or at risk of having a kidney injury, with an anti-KIM-1 antibody that specifically binds to a KIM-1 polypeptide of (SEQ ID NO: 1), and measuring the binding between the KIM-1 polypeptide and the anti-KIM-1 antibody;
b. comparing the level of the KIM-1 polypeptide in the blood sample with a reference level of the KIM-1 polypeptide;
c. selecting the subject as having a kidney injury or Renal Cell Carcinoma (RCC) when the level of KIM-1 polypeptide in the blood sample is 4-fold higher, or greater than 4-fold higher than the reference level for the KIM-1 polypeptide; and
d. administering an effective treatment for treating kidney disease to the subject selected as being diagnosed with a kidney injury or RCC.
US Pat. No. 10,709,789

LOW PROTEIN PERCENTAGE GELLING COMPOSITIONS

Keranetics, Inc., Winsto...

1. A composition comprising keratose, kerateine or a combination thereof, wherein said composition forms a hydrogel at a protein concentration of less than 20%,wherein said keratose, kerateine or combination thereof is prepared by a method including dialyzing said keratose, kerateine or combination thereof at a transmembrane pressure of from about 30 psi to about 70 psi, and
wherein said hydrogel exhibits a dynamic complex viscosity of at least 113.9 Pascals as measured at 25.degree. Celsius at a frequency of 1 Hertz.
US Pat. No. 10,710,045

CAPSULES CONTAINING MAMMALIAN CELLS

CAPSUM, Marseilles (FR)

1. A microcapsule comprising:a liquid core;
a stiff intermediate envelope comprising at least one biopolymer; and
at least one external envelope totally encapsulating the liquid core at its periphery,
said intermediate envelope being located between the liquid core and the external envelope,
said external envelope being able to retain the liquid core when the microcapsule is immersed in a gas and comprising at least one gelled polyelectrolyte and/or one stiffened biopolymer,
said microcapsule further comprising at least one eukaryotic mammalian cell, wherein the liquid core comprises at least one keratinocyte and the intermediate envelope comprises at least one fibroblast; and
said stiff intermediate envelope having an elastic modulus that is non-zero.
US Pat. No. 10,711,070

METHOD FOR PREPARING SPHERICAL CELLULOID BEADS

The United States of Amer...

1. A method of preparing solid, spherical celluloid beads comprising:a. preparing a suspension solution consisting essentially of water and gelatin wherein the gelatin is dissolved in the water and the density of the suspension solution is about 1.1 g/cm3 to 1.2 g/cm3 compared to water at 1.0 g/cm3;
b. preparing a celluloid solution comprising celluloid in a solvent and adding a co-solvent to adjust the density of the celluloid solution to about 1.1 g/cm3 to 1.59 g/cm3, compared to water at 1.0 g/cm3, wherein the density of the celluloid solution is equal to or greater than the density of the suspension solution, wherein the celluloid is dissolved in the solvent and the co-solvent, and wherein the solvent and the co-solvent are miscible with each other, immiscible in water, and have a boiling point lower than water;
c. adding the celluloid solution to the suspension solution to form droplets of the celluloid wherein the droplets of the celluloid are suspended in the suspension solution to create a system;
d. agitating the system to create an agitated system comprising droplets of the celluloid suspended in the suspension solution;
wherein the droplets of the celluloid are spherical; and
e. heating the agitated system to between 25° C. and less than the boiling point of water to remove the solvent and the co-solvent from the agitated system to form solid, spherical celluloid beads wherein the diameter of the solid, spherical celluloid beads is about 0.14 mm to 1.02 mm.
US Pat. No. 10,712,350

DIAGNOSIS OF SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

1. A method of treating a human subject that has or is suspected to have sepsis, the method comprising identifying the human subject with sepsis or an increased risk of sepsis by:(a) detecting the level of antitrypsin (ATT) or fragments thereof in a sample taken from said human subject using surface enhanced laser desorption ionization-time of flight-mass spectrometry (SELDI-TOF MS), immunoassays or a combination thereof, wherein the ATT fragments are selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14 or a combination thereof, and wherein said sample is a plasma sample, a serum sample, a whole blood sample, a blood sample or fractions thereof, a lymphatic fluid sample, a urine sample or an extract of any of the aforementioned samples;
(b) correlating the level of ATT or fragments thereof with having sepsis or an increased risk of sepsis and, wherein
said having sepsis or increased risk of sepsis is identified if the level of ATT is below a certain cut-off value and/or the level of fragments thereof is above a certain cut-off value;
(c) detecting the level of transthyretin (TTR) using SELDI-TOF MS, immunoassays or a combination thereof the sample taken from said human subject,
(d) correlating the level of TTR with sepsis or an increased risk of sepsis and, wherein
said sepsis or increased risk of sepsis is identified if the level of TTR is below a certain cut-off value; and
(e) administering antimicrobial therapy to the human subject with sepsis or an increased risk of sepsis.
US Pat. No. 10,710,046

PREPARATION OF TEMPLATES FOR NUCLEIC ACID SEQUENCING

Illumina Cambridge Limite...

1. A method comprising,(i) amplifying a template using amplification primers on a solid support to produce a plurality of double-stranded nucleic acid molecules such that both strands of each double-stranded nucleic acid molecule are attached to the solid support at their 5? ends, wherein a subset of the amplification primers comprise a cleavage site and wherein the cleavage site is positioned in a double-stranded region of each double-stranded molecule; and
(ii) cleaving only one strand of the double stranded molecules at the cleavage site to produce a cleaved strand and an un-cleaved strand.
US Pat. No. 10,711,071

METHOD FOR MODIFYING A NATURAL RUBBER, AND MODIFIED NATURAL RUBBER

COMPAGNIE GENERALE DES ET...

1. A process for modifying a natural rubber, comprising at least the following steps:i. providing at least one natural rubber and epoxidizing said natural rubber to obtain an epoxidized natural rubber, or providing a pre-epoxidized natural rubber,
ii. grafting, to said epoxidized natural rubber or to said pre-epoxidized natural rubber, at least one 1,3-dipolar compound having at least one nitrogen atom.
US Pat. No. 10,712,351

METHODS FOR EVALUATION OF THE EFFECTIVENESS OF A DRUG OR DRUG CANDIDATE IN TREATING AN INFLAMMATORY BOWEL DISEASE BY USE OF MULTIPLEXED ASSAY KIT COMPRISING VARIOUS BIOMARKERS

MESO SCALE TECHNOLOGIES, ...

1. A method for evaluation of the effectiveness of a drug and/or drug candidate in treating an inflammatory bowel disease (IBD) comprising the steps of:(a) performing an assay, with a kit comprising a multi-well assay plate, of a sample, the sample being a serum sample obtained from a human or a plasma sample obtained from a human, the multi-well assay plate comprising a plurality of wells, each well comprising at least four discrete binding domains with capture antibodies to which a plurality of biomarkers are bound, wherein said plurality of biomarkers comprise soluble Tumor Necrosis Factor receptor II (sTNFRII) and Macrophage Inflammatory Protein-1beta (MIP-1beta), and at least two additional biomarkers selected from the group consisting of eotaxin, Soluble Interleukin-6 Receptor (sIL-6R), Monocyte Chemoattractant Protein 1 (MCP-1), and Regulated on Activation, Normal T cell Expressed and Secreted protein (RANTES), said kit further comprising in one or more vials, containers, or compartments, a set of labeled detection antibodies specific for said plurality of biomarkers;
(b) determining a first ratio of sTNFRII to MIP-1beta in the sample;
(c) determining a second ratio of sTNFRII to MIP-1beta in a group of patients not diagnosed with IBD;
(d) comparing the first ratio to the second ratio;
(e) determining from said comparing step (d) the effectiveness of the drug or drug candidate; and
(f) administering to the human an effective amount of a drug for treatment of the IBD.
US Pat. No. 10,711,072

METHODS AND SYSTEMS FOR OLEFIN POLYMERIZATION

Univation Technologies, L...

1. A method for controlling polymer particle morphology in olefin polymerization, comprising:flowing a catalyst through a first concentric flow path of an injection nozzle having two or more concentric flow paths and into a fluidized bed disposed within a reactor;
flowing a feed comprising one or more monomers, one or more inert fluids, or a combination thereof through a second concentric flow path of the injection nozzle and into the fluidized bed;
contacting one or more monomers with the catalyst within the fluidized bed at conditions sufficient to produce a polyolefin;
determining a polymer particle morphology for the polyolefin, wherein the polymer particle morphology includes fines;
controlling an amount of the fines in the polymer particle morphology through a change to one or more of:
i) a temperature of the second concentric flow path or
ii) a flow rate of the feed through the second concentric flow path, wherein controlling the amount of fines by increasing one or more of the temperature and the flow rate increases the amount of fines produced by 1 percent (%) to about 200%, and wherein controlling the amount of fines by decreasing one or more of the temperature and the flow rate decreases the amount of fines produced by 2% to about 75%; and
contacting one or more monomers with the catalyst within the fluidized bed at conditions sufficient to produce a polyolefin having a controlled amount of fines.
US Pat. No. 10,711,073

METHOD OF MAKING A BRANCHED POLYMER, A BRANCHED POLYMER AND USES OF SUCH A POLYMER

SYNTHOMER (UK) LIMITED, ...

1. A method of making a branched water-soluble polymer comprising (C?C)—(C?C)—CO groups, the method comprising:(i) Providing, in admixture, at least one monofunctional monomer comprising one polymerisable carbon-carbon double bond per monomer, at least one multifunctional monomer comprising at least two polymerisable carbon-carbon double bonds per monomer, and at least one chain transfer agent comprising an aldehyde or a ketone;
(ii) Forming a polymer from the mixture in a free radical polymerisation reaction; and
(iii) Hydrolysing the polymer thereby forming a hydrolysed, water-soluble polymer, wherein the ratio of the number of moles of chain transfer agent comprising an aldehyde or ketone to the number of moles of multifunctional monomer is at least 10:1 and no more than 300:1.
US Pat. No. 10,709,793

GENE/CARRIER COMPLEX FOR PREVENTING OR TREATING INFLAMMATORY DISEASES

INDUSTRY-UNIVERSITY COOPE...

1. A gene/carrier complex comprising:one or more shRNAs selected from the group consisting of SEQ ID NOS: 2 to 5, which inhibit expression of a tumor necrosis factor-alpha converting enzyme (a TNF-? converting enzyme, TACE); and
a nonviral gene carrier,wherein the nonviral gene carrier comprises a trifluoroacetic acid (TFA) salt of poly(oligo-aspartic acid)(oligo-arginine).
US Pat. No. 10,711,074

SUPER ABSORBENT POLYMER AND METHOD FOR PREPARING SAME

LG Chem, Ltd., (KR)

1. A method for preparing a super absorbent polymer comprising:preparing a monomer composition containing a water soluble ethylenically unsaturated monomer, an internal crosslinking agent, and a polymerization initiator;
mixing the monomer composition with a laponite colloidal solution containing 0.02 to 0.09 part by weight of a positively charged laponite based on 100 parts by weight of the monomer composition to form a mixture of the monomer composition and the lapnotie colloidal solution; and
thermally polymerizing or photo-polymerizing the mixture of the monomer composition and the laponite colloidal solution to form a crosslinked polymer.
US Pat. No. 10,712,354

METHOD OF ANALYZING DILUTED BIOLOGICAL SAMPLE COMPONENT

Leisure, Inc., Tokyo (JP...

1. A method of quantitative analysis of a component to be analyzed in a blood sample,-the method comprising:(a) diluting a trace amount of the blood sample with a diluent buffer;
(b) measuring a concentration of an external standard substance in the blood sample diluted with the diluent buffer by absorbance, a Biuret method, a Bradford method, a Lowry method, a bromocresol green method, enzyme methods, using a flame photometer, using atomic absorption, or using an ion selective electrode,
wherein the external standard substance is selected from the group consisting of sodium,
wherein the external standard substance is a component homeostatically present comprised at a predetermined concentration in the blood sample prior to the dilution of the blood sample, and
wherein the diluent buffer has a pH 6.5 to 8.0 and is substantially free of the external standard substance; and
(c) calculating the dilution factor of the blood sample from the concentration of the external standard substance measured in (b).
US Pat. No. 10,709,795

METHOD FOR DELIVERING PHARMACEUTICAL NANOPARTICLES TO CANCER CELLS

National Guard Health Aff...

1. A method for delivering letrozole to cancer cells, comprising:administering a treatment composition comprising a carrier and a plurality of pharmaceutical nanoparticles to a patient to thereby deliver the letrozole to the cancer cells;
wherein the pharmaceutical nanoparticles having an interior space and a membrane surrounding the interior space,
wherein the interior space contains letrozole that is encapsulated by the membrane, and the membrane comprises;
a polylactide-block-poly(ethylene glycol)-block-polylactide block (PLA-PEG-PLA) copolymer wherein a number average molecular weight range of the PEG block is 800 Da to 3 kDa and a number average molecular weight range of each of the PLA block is from 1 kDa to 5 kDa,
a polyvinyl alcohol polymer,
bovine serum albumin in contact with the outer surface of the membrane, and
anti-Her2 antibody attached to the outer surface of the membrane.
US Pat. No. 10,712,356

APPARATUS AND METHOD FOR PICKING BIOLOGICAL SAMPLE

GENERAL AUTOMATION LAB TE...

1. A method of transferring a sample from at least one selected microwell of a microfabricated chip including a plurality of microwells to a predetermined location in a destination sample holder using a picking instrument comprising a picking pin having a distal tip, the picking pin having three degrees-of-freedom and configured to move in x, y, and z directions, the x, y directions constituting an x-y plane, the method comprising:calibrating the position of the microfabricated chip relative to the position of the picking pin;
determining the coordinates of the at least one selected microwell of the microfabricated chip for picking on the x-y plane relative to the position of the picking pin based on the calibration;
based on a current position of picking pin and the determined coordinates of the at least one selected microwell, moving the picking pin to a position above the location of the at least one selected microwell;
dipping at least a portion of the distal tip of the picking pin into the at least one selected microwell to pick up a sample contained in the at least one selected microwell; and
moving the picking pin and transferring the sample to a predetermined location in the destination sample holder.
US Pat. No. 10,709,796

OPTIMISED CODING SEQUENCE AND PROMOTER

UCL BUSINESS PLC, London...

1. A recombinant adeno-associated virus (AAV) particle comprising a heterologous nucleic acid sequence and a liver-specific promoter that is operably linked to and drives expression of said heterologous nucleic acid sequence, wherein said promoter has at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:3 and is less than 350 base pairs in length.
US Pat. No. 10,711,077

ZIEGLER-NATTA CATALYST COMPOSITION WITH CONTROLLED MORPHOLOGY

Fina Technology, Inc., H...

1. A process of forming a catalyst system comprising:reacting a hexane solution having 2-ethyl hexanol with a hexane solution comprising butyl ethyl magnesium (BEM) and triethyl aluminum (TEAl), wherein a TEAl to BEM molar ratio is about 0.5:1 to form a first compound comprising a non-reducing magnesium-aluminum alkoxide;
contacting the first compound with a first agent and a second agent in the presence of an inert hydrocarbon solvent to form a solution of reaction product “A”, the first agent consisting of titanium isopropoxide (Ti(OiPr)4) and the second agent comprising a first metal halide;
contacting the solution of reaction product “A” with a second metal halide to form a solid reaction product “B”;
washing the solid reaction product “B” with hexane;
contacting the solid reaction product “B” with a fourth agent to form a solid reaction product “C”, the fourth agent comprising a third metal halide, wherein the fourth agent contacts solid reaction product “B” in a molar equivalent of about 0.1;
optionally contacting the solid reaction product “C” with a fifth agent to form a solid reaction product “D”, the fifth agent comprising a fourth metal halide; and
contacting the solid reaction product “C” or “D” with a sixth agent to form a catalyst component, the sixth agent comprising a first organoaluminum compound, wherein the catalyst system is formed in the absence of ClTi(OiPr)3 and in the absence of a blend comprising TiCl4/titanium n-butoxide.
US Pat. No. 10,711,333

HIGH-STRENGTH STEEL SHEET AND METHOD FOR MANUFACTURING SAME

JFE STEEL CORPORATION, C...

1. A high-strength steel sheet having yield ratio of less than 68% and tensile strength of 980 MPa or more, the high-strength steel sheet comprising:a chemical composition containing, in mass %, C: 0.030% or more and 0.250% or less, Si: 0.01% or more and 3.00% or less, Mn: more than 4.20% and 6.00% or less, P: 0.001% or more and 0.100% or less, S: 0.0001% or more and 0.0200% or less, N: 0.0005% or more and 0.0100 or less, and Ti: 0.003% or more and 0.200% or less, and the balance being Fe and incidental impurities; and
a steel microstructure that contains, in area ratio, 15% or more and 55% or less of polygonal ferrite and 15% or more and 30% or less of martensite, and that contains, in volume fraction, 12% or more of retained austenite,
wherein the polygonal ferrite has a mean grain size of 4 ?m or less, the martensite has a mean grain size of 2 ?m or less, the retained austenite has a mean grain size of 2 ?m or less, and the polygonal ferrite, the martensite, and the retained austenite each have a mean grain aspect ratio of 2.0 or less, and
wherein a value obtained by dividing an Mn content in the retained austenite in mass % by an Mn content in the polygonal ferrite in mass % equals 2.0 or more.
US Pat. No. 10,711,079

METHOD FOR PRODUCING VINYL ETHER POLYMER HAVING HYDROXYL GROUP ON SIDE CHAIN AND TEMPERATURE-RESPONSIVE POLYMER MIXTURE

Maruzen Petrochemical Co....

1. A method for producing a vinyl ether polymer having a hydroxyl group on a side chain, comprising a step ofsubjecting a vinyl ether comprising a hydroxyl group to radical polymerization by using an oil-soluble azo polymerization initiator, in the presence of a mixed solvent comprising water and an organic solvent selected from alcohol or cyclic ether, and wherein a monomer conversion rate is 95% or more.
US Pat. No. 10,709,799

ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF

CytomX Therapeutics, Inc....

1. An activatable antibody that in an activated state binds Epidermal Growth Factor Receptor (EGFR) comprising:(a) an antibody or an antigen binding fragment thereof (AB) that specifically binds to EGFR, wherein the AB comprises:
(i) heavy chain complementarity determining regions (HCDRs), wherein the HCDRs are the HCDRs of a heavy chain amino acid sequence selected from the group consisting of: SEQ ID NO: 26, SEQ ID NO: 30, and SEQ ID NO: 34,
(ii) light chain complementarity determining regions (LCDRs), wherein the LCDRs are the LCDRs of light chain amino acid sequence SEQ ID NO: 68, and
(iii) a heavy chain comprising an amino acid sequence with at least one of the following amino acid sequence features: (1) a glutamine residue at the position corresponding to position 88 of SEQ ID NO: 26, SEQ ID NO: 30, and SEQ ID NO: 34, and (2) an alanine residue at the position corresponding to position 299 of SEQ ID NO: 26, SEQ ID NO: 30, and SEQ ID NO: 34;
(b) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB of the activatable antibody in an uncleaved state to EGFR, wherein the MM comprises the amino acid sequence CISPRGCPDGPYVMY (SEQ ID NO: 14); and
(c) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease,
wherein the activatable antibody in the uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: MM-CM-AB or AB-CM-MM.
US Pat. No. 10,710,055

SELECTIVE HYDROGENATION CATALYST FOR C3 HYDROCARBON CUTS FROM STEAM CRACKING AND/OR CATALYTIC CRACKING

IFP Energies nouvelles, ...

1. A catalyst consisting of palladium, and a porous support comprising at least one refractory oxide that is silica, alumina or silica-alumina, in which:the palladium content in the catalyst is in the range 0.0025% to 1% by weight with respect to the total weight of catalyst;
at least 80% by weight of the palladium is distributed in a crust at the periphery of the porous support, the thickness of said crust being in the range 100 to 400 ?m;
the specific surface area of the porous support is in the range 1 to 50 m2/g;
the metallic dispersion D of the palladium is less than 20%.
US Pat. No. 10,711,080

PROPYLENE COPOLYMERS

Basell Poliolefine Italia...

1. A film comprising:(i) a propylene 1-hexene copolymer comprising:
from about 5.5 to about 9.0% by weight, based upon a total weight of the copolymer, of 1-hexene derived units having
a) two melting temperature peaks in the DSC plot having a difference in height ranging from about 0 to about 5 mW;
b) a higher melting temperature, measured by DSC, ranging from about 141.0° C. to about 151.0° C.; and
c) Melt Flow Rate (MFR, measured according to ASTM D 1238, 230° C./2.16 kg) from about 3.5 to about 8.0 g/10 min.

US Pat. No. 10,711,372

SILICON CARBIDE EPITAXIAL WAFER MANUFACTURING METHOD, SILICON CARBIDE SEMICONDUCTOR DEVICE MANUFACTURING METHOD AND SILICON CARBIDE EPITAXIAL WAFER MANUFACTURING APPARATUS

Mitsubishi Electric Corpo...

1. A silicon carbide epitaxial wafer manufacturing apparatus comprising:a growth furnace performing epitaxial growth;
a first gas introduction port provided on a first side of the growth furnace and leading into the growth furnace a process gas for growing a silicon carbide epitaxial layer;
a second gas introduction port provided on the first side of the growth furnace and leading into the growth furnace a stabilization gas for nitriding, oxidizing or oxynitriding and stabilizing silicon carbide attached to an inner wall surface of the growth furnace;
a wafer holder having a mount surface on which a wafer is mounted;
a first gas exhaust port provided on a second side of the growth furnace that is opposite to the first side, the first gas exhaust port for exhausting the process gas; and
a plurality of second gas exhaust ports provided lower than the wafer holder and for exhausting the stabilization gas.

US Pat. No. 10,711,219

AUTOMOTIVE TRANSMISSION FLUID COMPOSITIONS FOR IMPROVED ENERGY EFFICIENCY

Infineum International Li...

1. A method of improving the fuel economy of a vehicle equipped with an automatic transmission, the method comprising lubricating the automatic transmission with an automatic transmission fluid comprising a major amount of an oil of lubricating viscosity and minor amounts of(a) one or more oil-soluble or dispersible molybdenum-containing compounds selected from the group consisting of molybdenum dithiocarbamates, molybdenum dialkyldithiophosphates, molybdenum alkyl xanthates, molybdenum alkylthioxanthates, and mixtures thereof,
(b) a reaction product of an isomerized alkenyl-substituted succinic anhydride and a polyamine characterized by structure (II):
wherein x and y are independently zero or integers from 1 to 30, where x+y is from 1 to 30, and z is zero or an integer from 1 to 10,(c) an ashless dispersant, and
(d) a metal-containing detergent,
thereby improving fuel economy by at least 0.9% in an FTP-75 test cycle relative to a comparative automatic transmission fluid comprising a major amount of the oil of lubricating viscosity, a minor amount of the reaction product (b), a minor amount of ashless dispersant (c), and a minor amount of metal-containing detergent (d), but no oil-soluble or dispersible molybdenum-containing compound (a),
wherein the automatic transmission fluid further exhibits comparable paper-on-steel (POS) friction and significant reduction in steel-on-steel (SOS) friction, relative to the comparative automatic transmission fluid so as to satisfy one or both of the following:
no more than a 3% reduction in static POS friction, measured using a D600 fiber plate against an SAE1035 tumbled steel plate on a small scale Low Velocity Friction Apparatus (LVFA) at about 80° C., relative to the comparative automatic transmission fluid, and no less than a 12% reduction in dynamic SOS friction, measured on a Falex block-on-ring apparatus according to JASO M358-2005 at about 80° C. and at 0.025 to 1.00 m/s; and/or
no more than a 9% reduction in static POS friction, measured using a D600 fiber plate against an SAE1035 tumbled steel plate on a small scale LVFA at about 80° C., relative to the comparative automatic transmission fluid, and no less than a 17% reduction in dynamic SOS friction, measured on a Falex block-on-ring apparatus according to JASO M358-2005 at about 110° C. and at 0.025 to 1.00 m/s.

US Pat. No. 10,711,216

ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME

ExxonMobil Chemical Paten...

1. A compound having a formula (F-I) below:
wherein:
R1 and R2 are independently each a hydrocarbyl group comprising at least 2 carbon atoms; and
R3 is a substituted or unsubstituted hydrocarbyl group.

US Pat. No. 10,711,214

PRODUCTION OF A CARBONACEOUS FEEDSTOCK MATERIAL FROM A WASTE CARBON SOURCE

NORTH-WEST UNIVERSITY, P...

1. A process for producing a carbonaceous feedstock material from waste-containing carbon sources, the process including the steps consisting of:(i) introducing a source of a hydrothermal liquefaction biochar product to a source of discard coal fines to form a bio-coal mixture;
(ii) introducing a gasification catalyst additive selected from the group consisting of a source of an alkali metal or a source of an alkaline earth metal to the bio-coal mixture;
(iii) optionally, contacting the bio-coal mixture with a binder; and
(iv) compacting the resulting mixture of step (ii) or (iii) to form one or more carbonaceous feedstock briquettes, the size of said briquettes having a dimension of at least 5 mm.

US Pat. No. 10,711,081

VINYL ALCOHOL-VINYL ACETATE COPOLYMER

TOKUSHIMA UNIVERSITY, To...

1. A method for producing a vinyl alcohol-vinyl acetate copolymer comprising a unit of vinyl alcohol and a unit of vinyl acetate, wherein the vinyl alcohol-vinyl acetate copolymer has a randomness value R of 0.5 or higher, and wherein the randomness value R is obtained using the following equation (1):
where LO represents a mean chain length of the unit of vinyl alcohol and LA represents a mean chain length of the unit of vinyl acetate,
the method comprising the step of:
transesterification of polyvinyl acetate or a raw material vinyl alcohol-vinyl acetate copolymer using a dianionic zincate complex represented by the following formula (2):
t-BunR4-nZnMm  (2)
where n represents an integer of 1 to 4, m represents 1 or 2, Rs may be the same as or different from one another when n represents 1 or 2 and each represent a C1-C8 alkyl, alkenyl, aryl, or arylalkyl group, and M represents lithium or magnesium.

US Pat. No. 10,711,005

COMPOUND I AND COMPOUND II AS WELL AS PREPARATION METHODS THEREFOR AND APPLICATION THEREOF

SHENZHEN UNIVERSITY, She...

1. A compound of formula I:

US Pat. No. 10,710,993

BENZOFURAN PYRAZOLE AMINE KINASE INHIBITOR

HANGZHOU REX PHARMACEUTIC...

1. A compound having the following general structural formula (I) or a pharmaceutically acceptable salt thereof:
Wherein R1 is selected from

R0, R8 and R9 are each independently selected from one or more of the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, acyl, amido, sulfo group, sulfanilamido, hydroxyl, aryl and heterocyclyl;
R2, R3, R4, R5, R6, R7, R10 and R11 are each independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, cyano and amino;
R13 is selected from one or more of the group consisting of hydrogen, C1-6 alkoxy, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, amido, boryl, amino, hydroxyl, cyano, carbonyl, carboxy, aryl and heterocyclyl;
R12 and R14 are each independently selected from one or more of the group consisting of hydrogen, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl, amino, amido, hydroxyl, carbonyl, ureido, sulfuryl, sulfamido, phosphoroso, boryl, aryl and heterocyclyl;
R10 and R11 each substitute at the pyrimidine of the parent nucleus, or R10 and R11 are linked to each other to form a 5-7 membered saturated or unsaturated carbocyclic or heterocyclic ring fused with the pyrimidine of the parent nucleus;
the heterocyclyl is a 3-12 membered heterocyclic ring containing one or more of N and O atoms;
m is selected from any integer from 0 to 3; p is selected from any integer from 0 to 6; andn is 1 or 2.

US Pat. No. 10,710,991

PROCESS FOR THE PREPARATION OF THIETANE DERIVATIVES

Syngenta Participations A...

1. A process for preparing a compound of formula X
comprising
i. reacting a compound of formula VII

with triphenylphosphoranyldiene-acetonitrile or (Cyanomethyl)diethoxyphosphine oxide to give a compound of formula VIII

ii. reducing the compound of formula VIII with a suitable reducing agent to give a compound of formula X.

US Pat. No. 10,710,990

METHOD FOR PRODUCING GLYCERIC ACID ESTER

KAO CORPORATION, Tokyo (...

1. A method of producing a compound represented by the following formula (II), comprising a step of oxidatively esterifying Compound A, Compound A being represented by the following formula (I), with Compound B, Compound B being selected from an organic nitroxyl radical, an N-hydroxy form thereof, and a salt containing an oxo ammonium cation of them, and an oxidizing agent, and in the presence of a pyridine having an alkyl substituent, wherein the molar ratio of Compound B to Compound A (B:A) used in the oxidative esterification is in the range from 0.0001:1 through 0.1:1:
wherein, in the formula (I), R1 and R2 each independently represent a hydrogen atom or a monovalent hydrocarbon group, or R1 and R2 are bonded to each other to form a divalent hydrocarbon group for constituting a ring structure; and

wherein, in the formula (II), R1 and R2 each independently represent a hydrogen atom or a monovalent hydrocarbon group, or R1 and R2 are bonded to each other to form a divalent hydrocarbon group for constituting a ring structure.

US Pat. No. 10,710,987

HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION

Epizyme, Inc., Cambridge...

1. A method of preparing a solid crystalline form of a N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide monohydrochloride, wherein the solid crystalline form exhibits an X-ray powder diffraction pattern having two or more peaks expressed in degrees 2-theta (+/?0.2), selected from the group consisting of 8.438, 10.083, 10.18, 10.74, 10.940, 11.22, 12.0, 13.116, 13.318, 13.418, 13.541, 13.762, 13.899, 16.443, 16.583, 17.026, 17.124, 17.219, 17.53, 17.78, 18.032, 18.32, 18.340, 18.419, 18.66, 19.399, 20.182, 20.199, 20.421, 20.500, 20.839, 21.14, 21.84, 21.917, 21.958, 22.22, 22.499, 23.238, 23.46, 23.725, 24.159, 24.363, 24.7, 24.958, 25.498, 26.222, 26.596, 26.863, 27.72, 30.30, 30.557, and 30.879, comprising the step of combining N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide with hydrochloric acid.

US Pat. No. 10,710,986

PD-1/PD-L1 INHIBITORS

Gilead Sciences, Inc., F...

1. A compound which is:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,710,985

INDOLIN-2-ONE DERIVATIVES

Hoffmann-La Roche Inc., ...

1. A compound of formula (I)
wherein
A is phenyl or a five or six membered heteroaryl group, containing one or two N atoms, selected from

or the amide group —C(O)—NR1R2 may form together with two neighboring carbon atoms from the group A an additional fused ring, selected from
R1 and R2 are independently selected from hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, —(CH2)2-lower alkoxy, oxetanyl, cycloalkyl, or CH2-cycloalkyl, which cycloalkyl rings are optionally substituted by halogen;or R1 and R2 may form together with the N atom to which they are attached the group
andR3 is hydrogen or lower alkyl;or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,710,984

N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N-[(PYRIDINYLAMINO)-PROPANYL]ARYLCARBOXAMIDES

Boehringer Ingelheim Inte...

1. A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,710,954

CONVERSION OF WOOD BASED HEMICELLULOSE PREHYDROLYSATE SUCCINIC ACID USING A HETEROGENEOUS ACID CATALAYST IN A BIPHASIC SYSTEM

1. A method of synthesizing succinic acid comprising:mixing a source of aqueous xylose with an organic solvent having low water solubility at a ratio of 1:1 to 1:5, wherein the organic solvent is selected from the group consisting of toluene, chloroform and ethyl acetate;
adding a suitable acid, thereby converting the xylose to furfural;
recovering an organic solvent phase comprising the furfural; and
adding hydrogen peroxide to the organic solvent phase comprising the furfural at a ratio of hydrogen peroxide to furfural of 1:1 to 1:5 in the presence of a macroreticular ion exchange catalyst having high acidic strength, said furfural transferring from the organic solvent phase to an aqueous phase comprising hydrogen peroxide and converting to succinic acid in the aqueous phase.

US Pat. No. 10,710,948

PROCESSES FOR PREPARING (R)-1-(5-CHLORO-[1,1?-BIPHENYL] -2-YL)-2,2,2-TRIFLUOROETHANOL AND 1-(5-CHLORO-[1,1?-BIPHENYL]-2-YL)-2,2,2-TRIFLUOROETHANONE

Roivant Sciences GmbH, B...

1. A process of preparing a compound of Formula A:comprising reducing a compound of Formula B:in the presence of a chiral catalyst.

US Pat. No. 10,710,929

MINERAL COMPOSITION BASED ON A MIXED SOLID PHASE OF CALCIUM AND MAGNESIUM CARBONATES AND PROCESS FOR PREPARING SUCH A COMPOSITION

S. A. Lhoist Recherche et...

1. A mineral composition containing a mixed solid phase of synthetic calcium and magnesium carbonates, formed of a crystallized calcic portion and a plate-like form crystallized magnesian portion, the crystals of the calcic portion and those of the magnesian portion being aggregated in a form of composite aggregates, these aggregates themselves being at least partly agglomerated in a form of agglomerates, said calcic portion comprising at least one carbonate selected from the group consisting of calcite and the mixtures of calcite and aragonite, said magnesian portion comprising hydromagnesite in the plate-like form, said aggregates being formed of a calcic core on which hydromagnesite plates are aggregated, said mixed solid phase of carbonates of said mineral composition having a thermal conductivity of 25 to 45 mW/Km for a bulk density of 250 kg/m3 or lower and of 80 kg/m3 or higher measured in accordance with standard EN 459.2, and a Ca/Mg molar ratio higher than 1.2 and equal to or less than 4.0.

US Pat. No. 10,710,792

AEROSOL CONTAINER WITH EASY-TO-OPERATE PUSH BUTTON

1. An aerosol container comprising:a main body filled with aerosol substance, wherein said main body is cylindrical in shape and includes a bottom end being entirely flat;
a nozzle disposed on a top end of said main body, wherein said nozzle includes a vertical portion and a horizontal portion, wherein said nozzle extends within said main body a predetermined depth and lies above said bottom end of said main body, wherein said horizontal portion is located at said top end of said vertical portion, wherein said top end of said vertical portion extends outwardly from said top end of said main body, wherein said horizontal portion forms a right angle with said vertical portion;
a pipe defined with a first end introduced in aerosol substance, a second end connected to said nozzle and a body therebetween; and
an actuating mechanism including a valve in connection with an internal body portion of said pipe, wherein said valve is actuated by a push button located on an outer surface of said main body, a rod mounted in a horizontal configuration connecting said push button and said valve, wherein said rod includes a spring mounted to an outer surface of said rod, wherein said rod and said spring are located entirely within said main body.

US Pat. No. 10,710,791

HAIR TREATMENT PROCESS THAT PROVIDES SHEEN USING AN AEROSOL DEVICE

1. A hair treatment process comprising:applying to the hair a composition comprising at least one fatty substance using an aerosol device, wherein the aerosol device comprises:
a container containing the composition and at least one propellant, wherein the at least one propellant possibly is present in the composition or in the container, separate from the composition; and
a diffuser for dispensing said composition, the diffuser comprising:
a body extending around a dispensing axis and being open at two opposite axial ends, and
an engaging part extending around the dispensing axis and being open at two opposite axial ends,
wherein the engaging part at least partially defines a dispensing orifice.

US Pat. No. 10,710,790

NESTED INSULATED PACKAGING

Pratt Corrugated Holdings...

1. A nested insulated packaging assembly comprising:an outer box including an outer top side wall, an outer bottom side wall, and a plurality of outer lateral side walls;
an inner corrugated cardboard portion positioned in the outer box, the inner corrugated cardboard portion including a plurality of inner lateral side walls, the plurality of inner later side walls defining a lateral outer surface and a lateral inner surface, the lateral inner surface disposed opposite from the lateral outer surface, the lateral inner surface at least partially defining an inner storage cavity within the inner corrugated cardboard portion, the lateral outer surface and the lateral inner surface each defined by corrugated cardboard;
a first thermal liner contacting the outer bottom side wall of the outer box; and
a second thermal liner contacting at least a first outer lateral side wall, a second outer lateral side wall, and a third outer lateral side wall of the plurality of outer lateral side walls of the outer box and at least a first inner lateral side wall, a second inner lateral side wall, and a third inner lateral side wall of the plurality of inner lateral side walls of the inner corrugated cardboard portion, the second thermal liner contacting the lateral outer surface, the second thermal liner comprising a left fold, a front fold, and a right fold, the second thermal liner defining an inner surface and an outer surface, a thickness of the second thermal liner being defined between the inner surface and the outer surface, a portion of the outer surface defined by the left fold contacting the first outer lateral side wall, a portion of the inner surface defined by the left fold contacting the first inner lateral side wall, a portion of the outer surface defined by the front fold contacting the second outer lateral side wall, a portion of the inner surface defined by the front fold contacting the second inner lateral side wall, a portion of the outer surface defined by the right fold contacting the third outer lateral side wall, a portion of the inner surface defined by the right fold contacting the third inner lateral side wall, the second thermal liner defining a first bend line between the left fold and the front fold, the portion of the inner surface defined by the left fold being connected to the portion of the inner surface defined by the front fold at the first bend line, the second thermal liner defining a second bend line between the front fold and the right fold, the portion of the inner surface defined by the front fold being connected to the portion of the inner surface defined by the right fold at the second bend line, the left fold defining a left side end of the second thermal liner, the right fold defining a right side end of the second thermal liner, the left side end defined opposite from the right side end, the thickness being uniform from the left side end to the right side end.

US Pat. No. 10,710,174

SLITTING CUTTER AND TOOL KEY IN COMBINATION THEREWITH

Iscar, Ltd., Tefen (IL)

1. A slitting cutter (20) comprising:a disk-shaped cutter body (22) having a cutter axis of rotation (AC) defining a direction of rotation (R) about the cutter axis of rotation (AC), opposing first and second body side surfaces (24a, 24b), and a body peripheral surface (26) extending therebetween,
a plurality of insert receiving portions (28) circumferentially spaced about the body peripheral surface (26) and a plurality of cutting inserts (30) removably retained therein,
at least radially outer portions of the first and second body side surfaces (24a, 24b) contained in first and second reference planes (P1, P2), respectively, the first and second reference planes (P1, P2) offset by a body width (WB),
each insert receiving portion (28) having first and second clamping jaws (32, 34) spaced apart by an insert receiving slot (36), the first clamping jaw (32) resiliently displaceable relative to the second clamping jaw (34) and having a resilient axis of rotation (AR),
each cutting insert (30) resiliently clamped in its respective insert receiving slot (36), and having a cutting edge (42) intersecting the first and second reference planes (P1, P2),
wherein:
the plurality of cutting edges (42) define an outer imaginary circle (CO) having an outer cutting diameter (DO), and the plurality of resilient axes of rotation (AR) define an inner imaginary circle (CI) having an inner cutting diameter (DI),
and wherein:
the number N of cutting inserts (30) resiliently clamped in the slitting cutter (20), is the inner cutting diameter (DI), in millimeters, multiplied by a spacing factor (FS), and the spacing factor (FS) is between 0.15 and 0.30.

US Pat. No. 10,710,041

CYLINDRICAL WALL FOR FILTERING SOLID PARTICLES IN A FLUID

Total Raffinage Chimie, ...

1. A cylindrical wall for filtering solid particles in a fluid, through which this fluid is to circulate, this wall comprisingat least one perforated plate having a finite radius of curvature, and
at least one grating element superposed on the perforated plate, the grating element comprising a plurality of rigid wires extending in a longitudinal direction and positioned adjacent to one another in order to filter the solid particles,
characterized in that
the grating element is arranged for the wires to be secured to one another only by means of links between adjacent wires, each link between two adjacent wires occupying only a portion of the length of the wires, and having a thickness less than or equal to the thickness of these wires in proximity to the link.

US Pat. No. 10,710,040

SYSTEMS FOR PROMOTING ENDOTHERMIC CONVERSIONS WITH OXYGEN TRANSFER AGENTS

EcoCatalytic Inc., Wobur...

1. A system for promoting endothermic conversions comprising:a) a first portion defining a first inner volume at least partially filled with an oxygen transfer agent;
b) a first supply containing one or more of hydrogen and a saturated hydrocarbon fluidly connected to a first inlet of the first inner volume;
c) a first outlet conveying one or more of carbon dioxide, water, and an unsaturated hydrocarbon from the first inner volume;
d) a second portion and a heat exchanger within the second portion, the second portion defining a second inner volume at least partially filled with reduced oxygen transfer agent, the heat exchanger defining a third inner volume segregated from the second inner volume;
e) a second supply containing an oxidizing agent fluidly connected to a second inlet to the second inner volume; and
f) a third supply fluidly connected to the third inner volume, wherein the third supply contains a saturated hydrocarbon and, optionally, water;
wherein the heat exchanger is configured to transfer heat resulting from the oxidation of the reduced oxygen transfer agent in the second inner volume to the third inner volume and the heat from the oxidation of the reduced oxygen transfer agent results in endothermic conversion of the saturated hydrocarbon in the third inner volume to an unsaturated hydrocarbon; and
wherein at least one of condition i) or condition ii) is met: i) the first supply additionally contains a sulfur containing gas; ii) the oxidizing agent is comprised of at least one oxide of sulfur.

US Pat. No. 10,710,039

DEVICE AND METHOD FOR LOADING PELLETS

Tubemaster, Inc., Louisv...

1. A method for loading porous pellets, comprising the steps of:providing a tubular member defining a bottom opening, a top opening, and a fluid flow path from said bottom opening to said top opening, with a screen across said fluid flow path which is sized with a small enough mesh to prevent a desired size of porous pellets from passing through said screen while allowing smaller-sized dust to pass through, wherein a lower portion of said tubular member below said screen defines a desired volume;
providing a vacuum line in fluid communication with said top opening of said tubular member;
creating an air flow along said fluid flow path and through said vacuum line, with a desired volume of porous pellets in said lower portion of said tubular member;
moving said tubular member to a position over a desired loading location; and then
reducing said upward flow of air sufficiently to allow said desired volume of porous pellets to fall down, through said lower portion of said tubular member.

US Pat. No. 10,710,037

CHEMICAL MIXING SYSTEM AND METHOD

DuBois Chemicals, Inc., ...

1. A method for mixing a concentrated liquid chemical detergent solution for use with a car wash application-level delivery system, comprising:receiving a base fluid into a mixing station having an injector assembly that includes at least one venturi chamber having at least one suction port in fluid communication with the at least one venturi chamber;
regulating the pressure of the base fluid to less than 40 psi;
providing a source of at least one super concentrate liquid chemical detergent component in fluid communication with the injector assembly via a first tube;
providing a receiving container for collection of a final concentrated liquid chemical detergent solution that is in fluid communication with the injector assembly via a second tube;
mixing the at least one super concentrate liquid chemical detergent component with the base fluid in the at least one venturi chamber to create a concentrated liquid chemical detergent solution, wherein a flow of the base fluid through the at least one venturi chamber of the injector assembly draws the at least one super concentrate liquid chemical detergent component through the at least one suction port and into the flow of the base fluid; and
dispensing the concentrated liquid chemical detergent solution into the receiving container, wherein the dispensed concentrated liquid chemical detergent solution is suitable for use with the car wash application-level delivery system to produce an application-level dilution of the chemical detergent component.

US Pat. No. 10,710,036

INSTALLATION AND METHOD FOR TREATING A PLASTIC MELT

Next Generation Recycling...

1. An installation (1) for treating a plastics melt, and setting the intrinsic viscosity thereof, having a reactor (2) which has a reactor housing (3) with at least one first reactor housing part (4) with an upper end region (6) and a lower end region (7) and which has a chamber part (8) extending between the upper and lower end regions (6, 7), wherein the first chamber part (8) has a vertical height extent, and the reactor housing (3) has, in the region of the lower end region (7) of the at least first reactor housing part (4), an at least second reactor housing part (5) which directly adjoins said first reactor housing part and which has a second chamber part (9), wherein the two chamber parts (8, 9) are connected to one another in terms of flow and are formed so as to be sealed off with respect to the external surroundings, and in the region of the upper end region (6) of the first reactor housing part (4), at at least one inlet opening, at least one feed line (10) for the plastics melt opens into the first reactor housing part (4), and at least one outlet opening (11) for the plastics melt is arranged in the second reactor housing part (5), and having at least one mixing element (12) which is arranged in the second reactor housing part (5), which mixing element (12) is mounted in the second reactor housing part (5) so as to be rotatable about an axis of rotation (13), and wherein the mixing element (12) is connected in terms of drive to a dedicated, independent first drive device (18),wherein the reactor (2) is supported on a standing surface with the interposition of at least one weight-determining device (21),
wherein a discharge device (19) for the plastics melt is arranged so as to adjoin the outlet opening (11) of the second reactor housing part (5), which discharge device is in the form of a melt pump or in the form of an extruder,
wherein the discharge device (19) is also supported on the standing surface with the interposition of at least one weight-determining device (21), and
wherein the discharge device (19) is connected in terms of drive to a second drive device (20), wherein the second drive device (20) is driven independently of the first drive device (18) of the mixing element (12).

US Pat. No. 10,710,035

FEED MIXTURE DISTRIBUTION DEVICE

OUTOTEC (FINLAND) OY, Es...

1. A feed mixture distribution device configured to evening out a feed of feed mixture in an annular feed mixture feed channel of a burner, wherein the feed mixture distribution device comprises:a cylindrical member having a cylindrical wall, a first end, a second end, and a longitudinal central axis X, and
wherein the cylindrical member is at the first end provided with rectangular flat plate means, which extend radially from the cylindrical wall of the cylindrical member and which are arranged symmetrically about the longitudinal central axis X of the cylindrical member,
wherein
the cylindrical wall of the cylindrical member is between the rectangular flat plate means and the second end provided with at least one helical plate means arranged symmetrically about the longitudinal central axis X of the cylindrical member,
each helical plate means extend towards the second end of the cylindrical wall of the cylindrical member in a helical manner about the longitudinal central axis X of the cylindrical member,
each helical plate means has a downstream end and a feed mixture bearing surface, wherein the width of the feed mixture bearing surface as measured along a line normal to the longitudinal central axis X of the cylindrical member decreases in a direction towards the downstream end of the helical plate means,
each helical plate means comprises an upstream helical plate section, which comprises a part of the feed mixture bearing surface and which extend towards the second end of the cylindrical member in a helical manner about the longitudinal central axis X of the cylindrical member and a downstream helical plate section, which comprises a part of the feed mixture bearing surface and which extend towards the second end of the cylindrical member in a helical manner about the longitudinal central axis X of the cylindrical member,
a slit between each upstream helical plate section of the helical plate means and each downstream helical plate section of the helical plate means,
the handedness of the upstream helical plate section of the helical plate means being different than the handedness of the downstream helical plate section of the helical plate means, and
the downstream end of the helical plate means being a part of the downstream helical plate section of the helical plate means.